

HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to US Provisional Patent Application 60/267,818 filed February 9, 2001 and US Provisional Patent Application 60/328,768 filed October 12, 2001, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention is in the field of medicinal chemistry and relates to pyrazole compounds that are protein kinase inhibitors, especially inhibitors of ERK, compositions containing such compounds and methods of use. The compounds are useful for treating cancer and other diseases that are alleviated by protein kinase inhibitors.

BACKGROUND OF THE INVENTION

Mammalian mitogen-activated protein (MAP) 1 kinases are serine/threonine kinases that mediate 5 intracellular signal transduction pathways (Cobb and Goldsmith, 1995, *J Biol. Chem.*, 270, 14843; Davis, 1995, *Mol. Reprod. Dev.* 42, 459). Members of the MAP kinase family share sequence similarity and conserved structural domains, and include the ERK2 (extracellular signal 10 regulated kinase), JNK (Jun N-terminal kinase), and p38 kinases. JNKs and p38 kinases are activated in response to the pro-inflammatory cytokines TNF-alpha and

interleukin-1, and by cellular stress such as heat shock, hyperosmolarity, ultraviolet radiation, lipopolysaccharides and inhibitors of protein synthesis (Derijard et al., 1994, *Cell* **76**, 1025; Han et al., 1994, *Science* **265**, 808; Raingeaud et al., 1995, *J Biol. Chem.* **270**, 7420; Shapiro and Dinarello, 1995, *Proc. Natl. Acad. Sci. USA* **92**, 12230). In contrast, ERKs are activated by mitogens and growth factors (Bokemeyer et al., 1996, *Kidney Int.* **49**, 1187).

ERK2 is a widely distributed protein kinase that achieves maximum activity when both Thr183 and Tyr185 are phosphorylated by the upstream MAP kinase kinase, MEK1 (Anderson et al., 1990, *Nature* **343**, 651; Crews et al., 1992, *Science* **258**, 478). Upon activation, ERK2 phosphorylates many regulatory proteins, including the protein kinases Rsk90 (Bjorbaek et al., 1995, *J. Biol. Chem.* **270**, 18848) and MAPKAP2 (Rouse et al., 1994, *Cell* **78**, 1027), and transcription factors such as ATF2 (Raingeaud et al., 1996, *Mol. Cell Biol.* **16**, 1247), Elk-1 (Raingeaud et al. 1996), c-Fos (Chen et al., 1993 *Proc. Natl. Acad. Sci. USA* **90**, 10952), and c-Myc (Oliver et al., 1995, *Proc. Soc. Exp. Biol. Med.* **210**, 162). ERK2 is also a downstream target of the Ras/Raf dependent pathways (Moodie et al., 1993, *Science* **260**, 1658) and may help relay the signals from these potentially oncogenic proteins. ERK2 has been shown to play a role in the negative growth control of breast cancer cells (Frey and Mulder, 1997, *Cancer Res.* **57**, 628) and hyperexpression of ERK2 in human breast cancer has been reported (Sivaraman et al., 1997, *J Clin. Invest.* **99**, 1478). Activated ERK2 has also been implicated in the proliferation of endothelin-stimulated airway smooth muscle cells,

suggesting a role for this kinase in asthma (Whelchel et al., 1997, Am. J. Respir. Cell Mol. Biol. 16, 589).

Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, 5 breast and other solid tumors. This kinase is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell 10 cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora-2 protein has been found to be overexpressed. See Bischoff et al., *EMBO J.*, 1998, 17, 3052-3065; Schumacher et al., *J. Cell Biol.*, 1998, 143, 1635-1646; Kimura et 15 al., *J. Biol. Chem.*, 1997, 272, 13766-13771.

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of α and β isoforms that are each encoded by distinct genes [Coghlan et al., *Chemistry & Biology*, 7, 793-803 (2000); Kim and Kimmel, *Curr. Opinion Genetics Dev.*, 10, 508-514 (2000)]. GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocyte hypertrophy [WO 99/65897; WO 00/38675; Haq et al., *J. Cell Biol.* (2000) 151, 117]. These diseases may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role. GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These proteins include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein

Tau, the gene transcription factor β -catenin, the translation initiation factor eIF2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPBA. These diverse protein targets
5 implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.

In a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes, insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis. Along this pathway, GSK-3 is a negative regulator of the insulin-induced signal. Normally, the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase.
10 The inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al., *PNAS*, **93**, 8455-9 (1996); Cross et al., *Biochem. J.*, **303**, 21-26 (1994); Cohen, *Biochem. Soc. Trans.*, **21**, 555-567 (1993); Massillon et al., *Biochem J.* **299**, 123-128 (1994)].
15 However, in a diabetic patient where the insulin response is impaired, glycogen synthesis and glucose uptake fail to increase despite the presence of relatively high blood levels of insulin. This leads to abnormally high blood levels of glucose with acute and long term effects that may ultimately result in cardiovascular disease, renal
20 failure and blindness. In such patients, the normal insulin-induced inhibition of GSK-3 fails to occur. It has also been reported that in patients with type II diabetes, GSK-3 is overexpressed [WO 00/38675].
25 Therapeutic inhibitors of GSK-3 therefore are considered to be useful for treating diabetic patients suffering from an impaired response to insulin.
30

20072695 - 20280202

GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known β -amyloid peptide and the formation of intracellular neurofibrillary tangles. The 5 neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition 10 of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al., *Current Biology* 4, 1077-86 (1994); Brownlee et al., *Neuroreport* 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.

15 Another substrate of GSK-3 is β -catenin which is degraded after phosphorylation by GSK-3. Reduced levels of β -catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death 20 [Zhong et al., *Nature*, 395, 698-702 (1998); Takashima et al., *PNAS*, 90, 7789-93 (1993); Pei et al., *J. Neuropathol. Exp.*, 56, 70-78 (1997)].

As a result of the biological importance of GSK-3, there is current interest in therapeutically 25 effective GSK-3 inhibitors. Small molecules that inhibit GSK-3 have recently been reported [WO 99/65897 (Chiron) and WO 00/38675 (SmithKline Beecham)].

Aryl substituted pyrroles are known in the literature. In particular, tri-aryl pyrroles (US 30 5,837,719) have been described as having glucagon antagonist activity. 1,5-Diarylpyrazoles have been described as p38 inhibitors (WO 9958523).


20071699-0208002

There is a high unmet medical need to develop new therapeutic treatments that are useful in treating the various conditions associated with ERK2 activation. For many of these conditions the currently available treatment options are inadequate.

Accordingly, there is great interest in new and effective inhibitors of protein kinase, including ERK2 inhibitors, that are useful in treating various conditions associated with protein kinase activation.

DESCRIPTION OF THE INVENTION

It has now been found that compounds of this invention and compositions thereof are effective as protein kinase inhibitors, especially as inhibitors of ERK2. These compounds have the general formula I:



20 or a pharmaceutically acceptable derivative thereof,
wherein:

Sp is a spacer group comprising a 5-membered heteroaromatic ring, wherein Ring A and QR² are attached to Sp at non-adjacent positions; and wherein 25 Sp has up to two R⁶ substituents, provided that two substitutable carbon ring atoms in Sp are not simultaneously substituted by R⁶; Z¹ and Z² are each independently selected from N or CH; T and O are each an independently selected linker group;

U is selected from $-\text{NR}^7-$, $-\text{NR}^7\text{CO}-$, $-\text{NR}^7\text{CONR}^7-$, $-\text{NR}^7\text{CO}_2-$,
 $-\text{O}-$, $-\text{CONR}^7-$, $-\text{CO}-$, $-\text{CO}_2-$, $-\text{OC(O)}-$, $-\text{NR}^7\text{SO}_2-$, $-\text{SO}_2\text{NR}^7-$,
 $-\text{NR}^7\text{SO}_2\text{NR}^7-$, or $-\text{SO}_2-$;

m and n are each independently selected from zero or one;

5 R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR,
or OH;

R² is selected from $-(\text{CH}_2)_y\text{R}^5$, $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$,
 $-(\text{CH}_2)_y\text{CH}(\text{R}^8)\text{CH}(\text{R}^5)_2$, $-\text{N}(\text{R}^4)_2$, or $-\text{NR}^4(\text{CH}_2)_y\text{N}(\text{R}^4)_2$;

y is 0-6;

10 R³ is selected from R⁷, R, $-(\text{CH}_2)_y\text{CH}(\text{R}^8)\text{R}$, CN,
 $-(\text{CH}_2)_y\text{CH}(\text{R}^8)\text{CH}(\text{R}^5)_2$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^8)\text{N}(\text{R}^4)_2$;

each R is independently selected from an optionally
substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀
aryl, a heteroaryl ring having 5-10 ring atoms, or a
heterocyclyl ring having 3-10 ring atoms;

15 each R⁴ is independently selected from R, R⁷, -COR⁷, -CO₂R,
 $-\text{CON}(\text{R}^7)_2$, $-\text{SO}_2\text{R}^7$, $-(\text{CH}_2)_y\text{R}^5$, or $-(\text{CH}_2)_y\text{CH}(\text{R}^5)_2$;

each R⁵ is independently selected from R, OR, CO₂R,
 $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂;

20 CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;

each R⁶ is independently selected from R⁷, F, Cl,
 $(\text{CH}_2)_y\text{N}(\text{R}^7)_2$, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,
CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;

each R⁷ is independently selected from hydrogen or an
25 optionally substituted C₁₋₆ aliphatic group, or two R⁷
on the same nitrogen are taken together with the
nitrogen to form a 5-8 membered heterocyclyl or
heteroaryl ring;

R⁸ is selected from R, $(\text{CH}_2)_w\text{OR}^7$, $(\text{CH}_2)_w\text{N}(\text{R}^4)_2$, or $(\text{CH}_2)_w\text{SR}^7$;

30 and

each w is independently selected from 0-4.

As used herein, the following definitions shall
apply unless otherwise indicated. The phrase "optionally

10071699-0208030

substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term "(un)substituted." Unless otherwise indicated, an optionally substituted group may have a substituent at 5 each substitutable position of the group, and each substitution is independent of the other.

The term "aliphatic" or "aliphatic group" as used herein means a straight-chain or branched C₁-C₁₂ hydrocarbon chain that is completely saturated or that 10 contains one or more units of unsaturation, or a monocyclic C₃-C₈ hydrocarbon or bicyclic C₆-C₁₂ hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" or "cycloalkyl"), that 15 has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. For example, suitable aliphatic groups include, but are not limited to, linear or branched or alkyl, alkenyl, alkynyl groups and hybrids 20 thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

The terms "alkyl", "alkoxy", "hydroxyalkyl", "alkoxyalkyl", and "alkoxycarbonyl", used alone or as part of a larger moiety includes both straight and 25 branched chains containing one to twelve carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.

The terms "haloalkyl", "haloalkenyl" and 30 "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br, or I.

K0071699 - 020303E

The term "heteroatom" means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term "nitrogen" includes a substitutable 5 nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted 10 pyrrolidinyl).

The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen 15 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring".

[0001] The term "heterocycle", 20 "heterocyclyl", or "heterocyclic" as used herein means non-aromatic, monocyclic, bicyclic or tricyclic ring systems having five to fourteen ring members in which one or more ring members is a heteroatom, wherein each ring in the system contains 3 to 7 ring members.

[0002] The term "heteroaryl", used alone or 25 as part of a larger moiety as in "heteroaralkyl" or "heteroaryalkoxy", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is 30 aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may

be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including 5 heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group are selected from halogen, -R°, -OR°, -SR°, 1,2-methylenedioxy, 1,2-10 ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), Ph substituted with R°, -O(Ph), O-(Ph) substituted with R°, -CH₂(Ph), -CH₂(Ph) substituted with R°, -CH₂CH₂(Ph), -CH₂CH₂(Ph) substituted with R°, -NO₂, -CN, -N(R°)₂, -NR°C(O)R°, -NR°C(O)N(R°)₂, -NR°CO₂R°, -NR°NR°C(O)R°, 15 -NR°NR°C(O)N(R°)₂, -NR°NR°CO₂R°, -C(O)C(O)R°, -C(O)CH₂C(O)R°, -CO₂R°, -C(O)R°, -C(O)N(R°)₂, -OC(O)N(R°)₂, -S(O)₂R°, -SO₂N(R°)₂, -S(O)R°, -NR°SO₂N(R°)₂, -NR°SO₂R°, -C(=S)N(R°)₂, 20 -C(=NH)-N(R°)₂, -(CH₂)_yNHC(O)R°, or -(CH₂)_yNHC(O)CH(V-R°)(R°), wherein each R° is independently selected from hydrogen, optionally substituted C₁₋₆ aliphatic, an unsubstituted 5-6 membered heteroaryl or 25 heterocyclic ring, phenyl (Ph), -O(Ph), or -CH₂(Ph)-CH₂(Ph), wherein y is 0-6; and V is a linker group. Substituents on the aliphatic group of R° are selected from NH₂, NH(C₁₋₄ aliphatic), N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O-(C₁₋₄ aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), -O(halo C₁₋₄ aliphatic), or halo C₁₋₄ aliphatic.

An aliphatic group or a non-aromatic 30 heterocyclic ring may contain one or more substituents. Suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring

are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: =O, =S, =NNHR*, =NN(R*)₂, =N-, =NNHC(O)R*, =NNHCO₂(alkyl), =NNHSO₂(alkyl), or =NR*, where each R* is independently

5 selected from hydrogen or an optionally substituted C₁₋₆ aliphatic. Substituents on the aliphatic group of R* are selected from NH₂, NH(C₁₋₄ aliphatic), N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O-(C₁₋₄ aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), -O(halo C₁₋₄ aliphatic), or halo C₁₋₄ aliphatic.

10 Substituents on the nitrogen of a non-aromatic heterocyclic ring are selected from -R*, -N(R*)₂, -C(O)R*, -CO₂R*, -C(O)C(O)R*, -C(O)CH₂C(O)R*, -SO₂R*, -SO₂N(R*)₂, -C(=S)N(R*)₂, -C(=NH)-N(R*)₂, or -NR*SO₂R*; wherein R* is

15 hydrogen, an optionally substituted C₁₋₆ aliphatic, optionally substituted phenyl (Ph), optionally substituted -O(Ph), optionally substituted -CH₂(Ph), or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring. Substituents 20 on the aliphatic group or the phenyl ring of R* are selected from NH₂, NH(C₁₋₄ aliphatic), N(C₁₋₄ aliphatic)₂, halogen, C₁₋₄ aliphatic, OH, O-(C₁₋₄ aliphatic), NO₂, CN, CO₂H, CO₂(C₁₋₄ aliphatic), -O(halo C₁₋₄ aliphatic), or halo C₁₋₄ aliphatic.


25 The term "alkylidene chain" refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation. The optional substituents are as described above for an aliphatic group.

30 The term "spacer group" refers to a group that separates and orients other parts of the molecule attached thereto, such that the compound favorably interacts with functional groups in the active site of an

1000216595-0208826

enzyme. As used herein, the spacer group separates and orients ring A and QR² within the active site such that they may form favorable interactions with functional groups which exist within the active site of the ERK2
5 enzyme. When the spacer group is a 5-membered heteroaromatic ring, ring A and QR² are attached at non-adjacent positions "B" and "C", and the 5-membered ring is attached to ring A at point "D" and to QR² at point "E" as illustrated below.

10



15 Preferably, the distance between "D" and "C" is 3.7 Å, the distance between "D" and "E" is 5.0 Å, the distance between "B" and "C" is 2.2 Å, and the distance between "B" and "E" is 3.5 Å, wherein each of the above described distances is plus/minus 0.2 Å.

20 The spacer group itself may also form additional interactions within the active site to further enhance inhibitory activity of the compounds. For example, when Sp is a pyrrole the pyrrole-NH may form an additional hydrogen bond within the active site of the ERK2 enzyme.

25 The term "linker group" means an organic moiety that connects two parts of a compound. Linkers are typically comprised of an atom such as oxygen or sulfur, a unit such as -NH-, -CH₂-, -CO-, or a chain of atoms, such as an alkylidene chain. The molecular mass of a

20074553-020802

linker is typically in the range of about 14 to 200. Examples of linkers include a saturated or unsaturated C₁-₆ alkylidene chain which is optionally substituted, and wherein up to two saturated carbons of the chain are

5 optionally replaced by -C(O)-, -C(O)C(O)-, -CONR⁷-,
-CONR⁷NR⁷-, -CO₂-, -OC(O)-, -NR⁷CO₂-, -O-, -NR⁷CONR⁷-,
-OC(O)NR⁷-, -NR⁷NR⁷-, -NR⁷CO-, -S-, -SO-, -SO₂-, -NR⁷-,
-SO₂NR⁷-, or -NR⁷SO₂-.

As used herein, linker group Q connects Sp with R². Q may also form additional interactions within the ERK2 binding site to further enhance the inhibitory activity of the compound. When Q is a carbonyl-containing moiety such as -C(O)-, -CO₂-, -OC(O)-, -C(O)C(O)-, -CONH-, -CO₂NH-, -CONHNH-, -NHCO-, -OC(O)NH-, or -NHCO₂-, or a sulfonyl-containing moiety such as -SO₂-, -SO₂NH-, or -NHSO₂-, the carbonyl or sulfonyl oxygen forms a hydrogen-bond with lysine 54 in the ERK2 binding site. When Q is an NH-containing moiety such as -CH₂NH- or -NHNH-, the NH-group forms a hydrogen-bond with aspartic acid residue 167 in the ERK2 binding site. When Q is a hydrophobic group such as an alkyl chain, -O-, or -S-, Q forms additional hydrophobic interactions within the ERK2 binding site.

R² forms hydrophobic interactions within the binding site of ERK2, especially with the side-chain carbons of lysine 54 and aspartic acid 167. R² may also form hydrophobic interactions with the glycine-rich loop which is made up of amino-acid residues 33-38. When R² is substituted, the substituents may form further interactions within the binding site to enhance the inhibitory activity of the compound. For example, when a substituent on R² is a hydrogen-bond donor or a hydrogen-bond acceptor, said substituent forms a hydrogen bond

2020/07/16 9:00 AM

with enzyme-bound water molecules that exist in the binding site.

As used herein, linker group T, when present, connects Sp with R¹. T may also form additional

5 interactions within the ERK2 binding site to further enhance the inhibitory activity of the compound. When T is carbonyl-containing such as -CO-, -CO₂-, -OCO-, -COCO-, -CONH-, -CO₂NH-, -CONHNH-, -NHCO-, or -NHCO₂-, or
10 sulfonyl-containing such as -SO₂-, -SO₂NH-, or -NHSO₂-, the carbonyl or sulfonyl oxygen forms a hydrogen-bond with the NH of glutamine 105 in the ERK2 binding site. When T is NH-containing such as -CH₂NH- or -NHNH-, the NH-group forms a hydrogen-bond with the carbonyl of glutamine 105. When T is a hydrophobic group such as an
15 alkyl chain, -O-, or -S-, T forms additional hydrophobic interactions with the side-chain carbons of glutamine 105 as well as isoleucine 84.

The binding interactions described herein between the compounds of this invention and the ERK2 binding site have been determined by molecular modeling programs that are known to those of ordinary skill in the art. These molecular modeling programs include QUANTA [Molecular Simulations, Inc., Burlington, Mass., 1992] and SYBYL [Molecular Modeling Software, Tripos
25 Associates, Inc., St. Louis, Mo., 1992]. As used herein, the amino acid numbering for the ERK2 enzyme corresponds to the Swiss-Prot database entry for accession #P28482. The Swiss-Prot database is an international protein sequence database distributed by the European
30 Bioinformatics Institute (EBI) in Geneva, Switzerland. The database can be found at www.ebi.ac.uk/swissprot.

The compounds of this invention are limited to those that are chemically feasible and stable.

Therefore, a combination of substituents or variables in the compounds described above is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible

5 compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

Unless otherwise stated, structures depicted
10 herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of
15 the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a
20 hydrogen by a deuterium or tritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbon are within the scope of this invention.

Compounds of formula I or salts thereof may be formulated into compositions. In a preferred embodiment,
25 the composition is a pharmaceutically acceptable composition. In one embodiment, the composition comprises an amount of the protein kinase inhibitor effective to inhibit a protein kinase, particularly ERK-2, in a biological sample or in a patient. In another
30 embodiment, compounds of this invention and pharmaceutical compositions thereof, which comprise an amount of the protein kinase inhibitor effective to treat or prevent an ERK-2-mediated condition and a

pharmaceutically acceptable carrier, adjuvant, or vehicle, may be formulated for administration to a patient.

The term "patient" includes human and
5 veterinary subjects.

The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for *in vitro* assay; biopsied material obtained from a mammal or
10 extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

Another aspect of this invention relates to a method of treating or preventing an ERK-2-mediated disease, which method comprises administering to a
15 patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable comprising said compound.

The term "ERK-2-mediated condition" or "disease", as used herein, means any disease or other
20 deleterious condition in which ERK-2 is known to play a role. The term "ERK-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with an ERK-2 inhibitor. Such conditions include, without limitation, cancer, stroke,
25 diabetes, hepatomegaly, cardiovascular disease including cardiomegaly, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders including asthma, inflammation, neurological disorders and hormone-related diseases.
30 The term "cancer" includes, but is not limited to the following cancers: breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin,

T00074699-000202

keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma,

5 papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-
10 rectum, large intestine, rectum, brain and central nervous system, and leukemia.

The present method is especially useful for treating a disease that is alleviated by the use of an inhibitor of ERK2 or other protein kinases. Although the 15 present compounds were designed as ERK2 inhibitors, it has been found that certain compounds of this invention also inhibit other protein kinases such as GSK3, Aurora2, Lck, CDK2, and AKT3.

Another aspect of the invention relates to 20 inhibiting ERK-2 activity in a biological sample, which method comprises contacting the biological sample with a compound of formula I, or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a 25 method of inhibiting ERK-2 activity in a patient, which method comprises administering to the patient a compound of formula I or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a 30 method of treating or preventing an Aurora-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically

20292626-06203020-00726699-00200700

effective amount of a compound of formula I or a pharmaceutically acceptable comprising said compound.

The term "Aurora-2-mediated condition" or "disease", as used herein, means any disease or other

5 deleterious condition in which Aurora is known to play a role. The term "Aurora-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with an Aurora-2 inhibitor. Such conditions include, without limitation, cancer. The
10 10 term "cancer" includes, but is not limited to the following cancers: colon, breast, stomach, and ovarian.

Another aspect of the invention relates to inhibiting Aurora-2 activity in a biological sample, which method comprises contacting the biological sample
15 15 with a compound of formula I, or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a
20 20 compound of formula I or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease, which method comprises administering to a
25 25 patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable comprising said compound.

The term "GSK-3-mediated condition" or "disease", as used herein, means any disease or other
30 30 deleterious condition or state in which GSK-3 is known to play a role. Such diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS-

10076599.200820

associated dementia, amyotrophic lateral sclerosis (AML),
multiple sclerosis (MS), schizophrenia, cardiomyocyte
hypertrophy, reperfusion/ischemia, and baldness.

One aspect of this invention relates to a
5 method of enhancing glycogen synthesis and/or lowering
blood levels of glucose in a patient in need thereof,
which method comprises administering to the patient a
therapeutically effective amount of a compound of formula
I or a pharmaceutically acceptable thereof. This method
10 is especially useful for diabetic patients. Another
method relates to inhibiting the production of
hyperphosphorylated Tau protein, which is useful in
halting or slowing the progression of Alzheimer's
disease. Another method relates to inhibiting the
15 phosphorylation of β -catenin, which is useful for
treating schizophrenia.

Another aspect of the invention relates to
inhibiting GSK-3 activity in a biological sample, which
method comprises contacting the biological sample with a
20 compound of formula I.

Another aspect of this invention relates to a
method of inhibiting GSK-3 activity in a patient, which
method comprises administering to the patient a compound
of formula I or a pharmaceutically acceptable composition
25 comprising said compound.

Inhibition of ERK2, Aurora2, CDK2, GSK-3, Lck,
or AKT3 kinase activity in a biological sample is useful
for a variety of purposes which are known to one of skill
in the art. Examples of such purposes include, but are
30 not limited to, blood transfusion, organ-
transplantation, biological specimen storage, and
biological assays.

10071639-020802

The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and

5 which does not destroy the pharmacological activity thereof.

The amount effective to inhibit protein kinase, for example, Aurora-2 and GSK-3, is one that measurably inhibits the kinase activity where compared to the

10 activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.

Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypolypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous,

intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional
and intracranial injection or infusion techniques.

Preferably, the compositions are administered orally,
5 intraperitoneally or intravenously.

Sterile injectable forms of the compositions of
this invention may be aqueous or oleaginous suspension.

These suspensions may be formulated according to
techniques known in the art using suitable dispersing or

10 wetting agents and suspending agents. The sterile
injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally-
acceptable diluent or solvent, for example as a solution
in 1,3-butanediol. Among the acceptable vehicles and

15 solvents that may be employed are water, Ringer's
solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed
as a solvent or suspending medium. For this purpose, any
bland fixed oil may be employed including synthetic mono-

20 or di-glycerides. Fatty acids, such as oleic acid and
its glyceride derivatives are useful in the preparation
of injectables, as are natural pharmaceutically-
acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil

25 solutions or suspensions may also contain a long-chain
alcohol diluent or dispersant, such as carboxymethyl
cellulose or similar dispersing agents which are commonly
used in the formulation of pharmaceutically acceptable
dosage forms including emulsions and suspensions. Other

30 commonly used surfactants, such as Tweens, Spans and
other emulsifying agents or bioavailability enhancers
which are commonly used in the manufacture of
pharmaceutically acceptable solid, liquid, or other

dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally

5 acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added.

10 For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or

15 coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-

20 irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this

25 invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily

30 prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation

(see above) or in a suitable enema formulation.

Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical

compositions may be formulated in a suitable ointment.

5 containing the active component suspended or dissolved in
one or more carriers. Carriers for topical
administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid
petrolatum, white petrolatum, propylene glycol,
10 polyoxyethylene, polyoxypropylene compound, emulsifying
wax and water. Alternatively, the pharmaceutical
compositions can be formulated in a suitable lotion or
cream containing the active components suspended or
dissolved in one or more pharmaceutically acceptable
15 carriers. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60,
cetyl esters wax, cetearyl alcohol, 2-octyldecanol,
benzyl alcohol and water.

For ophthalmic use, the pharmaceutical

compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability,

fluorocarbons, and/or other conventional solubilizing or dispersing agents.

In addition to the compounds of this invention, pharmaceutically acceptable derivatives of the compounds 5 of this invention may also be employed in compositions to treat or prevent the above-identified diseases or disorders.

A "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt 10 of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored 15 derivatives are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent 20 compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids 25 and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, 30 fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-

10074595 - 6200802

naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

10 Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and $N^+(C_{1-4} \text{ alkyl})_4$ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

15 The amount of the protein kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated and the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

20 It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of

2007/10/09 10:20:02

the inhibitor will also depend upon the particular compound in the composition.

The kinase inhibitors of this invention or pharmaceutical compositions thereof may also be

5 incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However,

10 patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Suitable coatings and the

15 general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene

20 glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release

25 characteristics in the composition. Implantable devices coated with a kinase inhibitor of this invention are another embodiment of the present invention.

Depending upon the particular protein kinase-mediated condition to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention. For example, in the treatment of cancer other

1000746637020303020

chemotherapeutic agents or other anti-proliferative agents may be combined with the protein kinase inhibitors of this invention to treat cancer. These agents include, without limitation, adriamycin, dexamethasone,
5 vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.

Other examples of agents the inhibitors of this invention may also be combined with include, without limitation, agents for treating diabetes such as insulin
10 or insulin analogues, in injectable or inhalation form, glitazones, alpha glucosidase inhibitors, biguanides, insulin sensitizers, and sulfonyl ureas; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase
15 inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents
20 for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency
25 disorders such as gamma globulin.


Those additional agents may be administered separately from the protein kinase inhibitor-containing composition, as part of a multiple dosage regimen.

00071699-020802

Alternatively, those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor of this invention in a single composition.


Compounds of this invention may exist in 5 alternative tautomeric forms. Unless otherwise indicated, the representation of either tautomer is meant to include the other.

Accordingly, the present invention relates to compounds of formula I wherein Ring A is a pyridine (II), 10 pyrimidine (III), or triazine (IV) ring as shown below:



15 or a pharmaceutically acceptable derivative thereof, wherein Sp, T_mR¹, R², U_nR³, Q, and T are as described above.

Examples of suitable Sp groups of formula I include pyrrole (a), imidazole (b), pyrazole (c), 20 triazole (d), oxazole (e), isoxazole (f), 1,3-thiazole (g), 1,2-thiazole (h), furan (i), and thiophene (j), as shown below:



wherein each of a through j is optionally substituted with R⁶.

Preferred T_mR¹ groups of formula I are selected
5 from hydrogen, N(R⁴)₂, OH, 3-6 membered carbocyclyl, or an
optionally substituted group selected from C₁₋₆ aliphatic
or a 5-6 membered aryl or heteroaryl ring. When R¹ is an
optionally substituted phenyl or aliphatic group,
preferred substituents on the phenyl or aliphatic group
10 are R⁷, halo, nitro, alkoxy, and amino. Preferred T_mR¹
groups are methyl, ethyl, propyl, cyclopropyl,
cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃,
and CH₂NHCH₃. More preferred T_mR¹ groups of formula I are
those listed in Table 1 below.

15 Preferred R³ groups of formula I are hydrogen,
carbocyclyl, -CH(R⁸)R, or an optionally substituted group
selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic,
or a 5-6 membered aryl or heteroaryl ring. Examples of
such groups include methyl, ethyl, propyl, cyclopropyl,
20 cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and
isopropyl. When R³ is optionally substituted phenyl,
preferred substituents on the phenyl ring are halogen,
alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF₃, OH,
SO₂NH₂, and methylene dioxy. When R³ is -CH(R⁸)R, examples
25 of such groups include -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl,
-CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, and
-CH(CH₂OH)CH₂cyclopropyl. Preferred U_n groups, when
present, are -CH₂-, -O-, -NR⁷-, -NHCO-, and -NHCO₂-. More
preferred U_nR³ groups of formula I are those listed in
30 Table 1 below.

When R² is R⁵, preferred R⁵ groups are
pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and
piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-

T-0071699-020002

piperazine-1-yl, wherein each group is optionally substituted. When R^2 is $(CH_2)_yR^5$, $(CH_2)_yCH(R^5)_2$, or $-N(R^4)_2$, preferred R^5 groups are further selected from pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-

5 tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, benzyl, $-CH_2OH$, $-(CH_2)_2OH$, and isopropyl, wherein each group is optionally substituted. Preferred substituents on R^5 are $-OH$, pyridyl, piperidinyl, and optionally substituted phenyl. When R^2 is

10 $-(CH_2)_yCH(R^8)CH(R^5)_2$, preferred R^8 groups are R^7 and OR^7 such as OH and CH_2OH and preferred R^5 are as described above. Preferred $-(CH_2)_yCH(R^8)CH(R^5)_2$ groups of formula I are $-CH(OH)CH(OH)phenyl$ and $-CH(Me)CH(OH)phenyl$. Other preferred $-QR^2$ groups are those listed in Table 1 below.

15 Preferred compounds of formula I are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

- (a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR^1 is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring;
- (c) Q is $-CO-$, $-CO_2-$, $-CONH-$, $-SO_2-$, $-SO_2NH-$, $-OC(O)NH-$, $-C(O)ONH-$, or $-CONHNH-$;
- (d) R^2 is $-NR^4(CH_2)_yN(R^4)_2$, $-(CH_2)_yR^5$, $-(CH_2)_yCH(R^5)_2$, or $-(CH_2)_yCH(R^8)CH(R^5)_2$;
- (e) R^4 is R, R^7 , or $-(CH_2)_yCH(R^5)_2$; and

(g) R^5 is an optionally substituted group selected from C₁₋₆ aliphatic, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

More preferred compounds of formula I are those

5 having one or more, more preferably more than one, or most preferably all, of the features selected from the group consisting of:

(a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or an optionally substituted phenyl, benzyl, or isoxazolyl group;


10 (b) T_mR^1 is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAc, NHC(O)NHCH₃, or CH₂NHCH₃;

15 (c) Q is -CO-, -CONH-, -SO₂-, or -SO₂NH-;

(d) R^2 is -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂, or
20 -(CH₂)_yCH(R⁸)CH(R⁵)₂, wherein R⁸ is OH or CH₂OH;
and

(e) R^5 is -CH₂OH, -(CH₂)₂OH, isopropyl, or an
optionally substituted group selected from
25 pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl,
piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

30 A preferred embodiment of this invention relates to compounds of formula I':



I'

or a pharmaceutically acceptable derivative thereof,

5 wherein:

Sp is a spacer group comprising a 5-membered

heteroaromatic ring, wherein Ring A and Q'R²' are
attached to Sp at non-adjacent positions; and wherein
Sp has up to two R⁶ substituents, provided that two
10 substitutable carbon ring atoms in Sp are not
simultaneously substituted by R⁶;

Z¹ and Z² are each independently selected from N or CH;
Q' is selected from -CO₂-, -C(O)NR⁷- or -SO₂NR⁷-;

T is a linker group;

15 U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-,
-O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-,
-NR⁷SO₂NR⁷-, or -SO₂-;

m and n are each independently selected from zero or one;

R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR,
20 or OH;

R²' is selected from -(CH₂)_yCH(R⁵)₂ or -(CH₂)_yCH(R⁸)CH(R⁵)₂;

y is 0-6;

R³ is selected from R⁷, R, -(CH₂)_yCH(R⁸)R, CN,
-(CH₂)_yCH(R⁸)CH(R⁵)₂, or -(CH₂)_yCH(R⁸)N(R⁴)₂;

25 each R is independently selected from an optionally
substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀
aryl, a heteroaryl ring having 5-10 ring atoms, or a
heterocyclyl ring having 3-10 ring atoms;

2007/669620 20080202

each R⁴ is independently selected from R, R⁷, -COR⁷, -CO₂R,
-CON(R⁷)₂, -SO₂R⁷, -(CH₂)_yR⁵, or -(CH₂)_yCH(R⁵)₂;

each R⁵ is independently selected from R, OR, CO₂R,
(CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,

5 CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;

each R⁶ is independently selected from R⁷, F, Cl,
(CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,
CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;

each R⁷ is independently selected from hydrogen or an


10 optionally substituted C₁₋₆ aliphatic group, or two R⁷
on the same nitrogen are taken together with the
nitrogen to form a 5-8 membered heterocyclyl or
heteroaryl ring;

R⁸ is selected from R, (CH₂)_wOR⁷, (CH₂)_wN(R⁴)₂, or (CH₂)_wSR⁷;

15 and

each w is independently selected from 0-4.


Examples of suitable Sp groups of formula I'
include pyrrole (a), imidazole (b), pyrazole (c),
triazole (d), oxazole (e), isoxazole (f), 1,3-thiazole
20 (g), 1,2-thiazole (h), furan (i), and thiophene (j), as
shown below:



wherein each of a through j is optionally substituted
with R⁶.

25 Accordingly, the present invention relates to
compounds of formula I' wherein Ring A is a pyridine

(II'), pyrimidine (III'), or triazine (IV') ring as shown below:



or a pharmaceutically acceptable derivative thereof, wherein Sp., T_nR¹, Q_nR², and U_nR³ are as described above.

Preferred R⁵ groups of formula I' are R or OR⁷.

10 Examples of such groups include OH, CH₂OH, carbocyclic, or
optionally substituted 5 or 6-membered aryl or heteroaryl
rings, such as phenyl, pyridyl, and cyclohexyl.
Preferred R⁸ groups of formula I' are R and OR⁷, wherein R
is an optionally substituted group selected from C₁₋₄
15 aliphatic, 3-6 membered heterocyclic, or a 5-6 membered
aryl or heteroaryl ring. Examples of such groups include
phenyl, methyl, ethyl, OH, and CH₂OH. Preferred
substituents on the R⁵ aryl or heteroaryl ring are
halogen, haloalkyl, OR⁶, and R⁹.
20 Preferred T_mR¹ groups of formula I' are
hydrogen, N(R⁴)₂, OH, 3-6 membered carbocyclic, or an
optionally substituted group selected from C₁₋₆ aliphatic
or a 5-6 membered aryl or heteroaryl ring.. When R¹ is an
optionally substituted phenyl or aliphatic group,
25 preferred substituents on the phenyl or aliphatic group
are R⁷, halo, nitro, alkoxy, and amino. Preferred T_mR¹
groups include methyl, ethyl, propyl, cyclopropyl,
cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃,

and CH_2NHCH_3 . More preferred T_mR^1 groups of formula I' are those listed in Table 1 below.

Preferred R^3 groups of formula I' are hydrogen, carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group

5 selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and isopropyl. When R^3 is optionally substituted phenyl,
10 preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF_3 , OH, SO_2NH_2 , and methylene dioxo. When R^3 is $-\text{CH}(\text{R}^8)\text{R}$, examples of such groups include $-\text{CH}(\text{CH}_2\text{OH})\text{phenyl}$, $-\text{CH}(\text{CH}_2\text{OH})\text{ethyl}$, $-\text{CH}(\text{CH}_2\text{OH})_2$, $-\text{CH}(\text{CH}_2\text{OH})\text{isopropyl}$, and
15 $-\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{cyclopropyl}$. Preferred U_n groups, when present, are $-\text{CH}_2-$, $-\text{O}-$, $-\text{NR}^7-$, $-\text{NHCO}-$, and $-\text{NHCO}_2-$. More preferred U_nR^3 groups of formula I' are those listed in Table 1 below.

Preferred compounds of formula I' are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

(a) R^3 is hydrogen, carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
25 (b) T_mR^1 is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring; and
30 (c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.


More preferred compounds of formula I' are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

5 (a) R³ is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or an optionally substituted phenyl, benzyl, or isoxazolyl group;

10 (b) T_mR¹ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAc, NHC(O)NHCH₃, or CH₂NHCH₃; and

15 (c) R⁵ is OH, CH₂OH, carbocyclic, or an optionally substituted phenyl or pyridyl ring, and Q' is C(O)NH.

Another preferred embodiment of this invention relates to compounds of formula I":



or a pharmaceutically acceptable derivative thereof,
wherein:

Sp is a spacer group comprising a 5-membered

heteroaromatic ring, wherein Ring A and

$\text{C}(\text{O})\text{NHCH}[(\text{CH}_2)_{1-2}\text{OH}]R^5$ are attached to Sp at non-

adjacent positions; and wherein Sp has up to two R⁶ substituents, provided that two substitutable carbon ring atoms in Sp are not simultaneously substituted by R⁶;

5 Z¹ and Z² are each independently selected from N or CH; T is a linker group; U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-, -O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-, -NR⁷SO₂NR⁷-, or -SO₂-;


10 m and n are each independently selected from zero or one; R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR, or OH; R³ is selected from R⁷, R, -(CH₂)_yCH(R⁸)R, CN, -(CH₂)_yCH(R⁸)CH(R⁵)₂, or -(CH₂)_yCH(R⁸)N(R⁴)₂;

15 each R is independently selected from an optionally substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀ aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms; each R⁴ is independently selected from R, R⁷, -COR⁷, -CO₂R, -CON(R⁷)₂, -SO₂R⁷, -(CH₂)_yR⁵, or -(CH₂)_yCH(R⁵)₂; each R⁵ is independently selected from R, OR, CO₂R, (CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂, CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂; each R⁶ is independently selected from R⁷, F, Cl, (CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂, CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂; each R⁷ is independently selected from hydrogen or an optionally substituted C₁₋₆ aliphatic group, or two R⁷ on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; R⁸ is selected from R, (CH₂)_wOR⁷, (CH₂)_wN(R⁴)₂, or (CH₂)_wSR⁷; and

10071699-020302


each w is independently selected from 0-4.

Examples of suitable Sp groups of formula I" include pyrrole (a), imidazole (b), pyrazole (c), triazole (d), oxazole (e), isoxazole (f), 1,3-thiazole (g), 1,2-thiazole (h), furan (i), and thiophene (j), as shown below:




wherein each of a through j is optionally substituted with R⁶.

Accordingly, the present invention relates to compounds of formula I" wherein Ring A is a pyridine (II"), pyrimidine (III"), or triazine (IV") ring as shown below:



15



or a pharmaceutically acceptable derivative thereof, wherein Sp, T_6R^1 , U_6R^3 , and R^5 are as described above.

Preferred T_mR^1 groups of formula I" are

hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an

5 optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring. When R¹ is an optionally substituted phenyl or aliphatic group, preferred substituents on the phenyl or aliphatic group are R⁷, halo, nitro, alkoxy, and amino. Examples of
10 preferred T_mR¹ groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃, and CH₂NHCH₃. More preferred T_mR¹ groups of formula I" are those listed below in Table 1.

Preferred R³ groups of formula I" are hydrogen,

15 carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and 20 isopropyl. When R³ is optionally substituted phenyl, preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF₃, OH, SO₂NH₂, and methylene dioxy. When R³ is $-\text{CH}(\text{R}^8)\text{R}$, examples 25 of such groups include $-\text{CH}(\text{CH}_2\text{OH})\text{phenyl}$, $-\text{CH}(\text{CH}_2\text{OH})\text{ethyl}$, $-\text{CH}(\text{CH}_2\text{OH})_2$, $-\text{CH}(\text{CH}_2\text{OH})\text{isopropyl}$, and 30 $-\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{cyclopropyl}$. Preferred U_n groups, when present, are $-\text{CH}_2-$, $-\text{O}-$, $-\text{NR}^7-$, $-\text{NHCO}-$, and $-\text{NHCO}_2-$. More preferred U_nR³ groups of formula I" are those listed in 35

Preferred R⁵ groups of formula I" are optionally substituted 6-membered aryl, heteroaryl, and carbocyclic rings, such as phenyl, pyridyl, and cyclohexyl.

Preferred compounds of formula I["] are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

5 (a) R³ is hydrogen, carbocyclyl, -CH(R⁸)R, or an
 optionally substituted group selected from C₁₋₄
 aliphatic, 3-6 membered heterocyclic, or a 5-6
 membered aryl or heteroaryl ring;

10 (b) T_mR¹ is hydrogen, N(R⁴)₂, OH, 3-6 membered
 carbocyclyl, or an optionally substituted group
 selected from C₁₋₆ aliphatic or a 5-6 membered
 aryl or heteroaryl ring; and

15 (c) R⁵ is an optionally substituted 6-membered aryl,
 heteroaryl, or carbocyclic ring.


More preferred compounds of formula I["] are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

20 (a) R³ is selected from hydrogen, methyl, ethyl,
 propyl, cyclopropyl, cyclohexyl, isopropyl,
 -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂,
 -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or
 an optionally substituted phenyl or benzyl
 group;

25 (b) T_mR¹ is selected from optionally substituted
 phenyl, methyl, ethyl, propyl, cyclopropyl,
 cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAc,
 NHC(O)NHCH₃, or CH₂NHCH₃; and

30 (c) R⁵ is cyclohexyl or an optionally substituted
 phenyl or pyridylring.

Another preferred embodiment of this invention relates to compounds of formula I[°]:



or a pharmaceutically acceptable derivative thereof,

5 wherein:

Sp is a spacer group comprising a 5-membered heteroaromatic ring, wherein Ring A and

C(O)NHCH(R⁸)CH(R⁵)₂ are attached to Sp at non-adjacent positions; and wherein Sp has up to two R⁶

10 substituents, provided that two substitutable carbon ring atoms in Sp are not simultaneously substituted by R⁶;

Z¹ and Z² are each independently selected from N or CH;

T is a linker group;

15 U is selected from -NR⁷-, -NR⁷CO-, -NR⁷CONR⁷-, -NR⁷CO₂-, -O-, -CONR⁷-, -CO-, -CO₂-, -OC(O)-, -NR⁷SO₂-, -SO₂NR⁷-, -NR⁷SO₂NR⁷-, or -SO₂-;

m and n are each independently selected from zero or one;

R¹ is selected from hydrogen, CN, halogen, R, N(R⁷)₂, OR,

20 or OH;

y is 0-6;

R³ is selected from R⁷, R, -(CH₂)_yCH(R⁸)R, CN, -(CH₂)_yCH(R⁸)CH(R⁵)₂, or -(CH₂)_yCH(R⁸)N(R⁴)₂;

each R⁴ is independently selected from R, R⁷, -COR⁷, -CO₂R, -CON(R⁷)₂, -SO₂R⁷, -(CH₂)_yR⁵, or -(CH₂)_yCH(R⁵)₂;

each R is independently selected from an optionally

substituted group selected from C₁₋₆ aliphatic, C₆₋₁₀

aryl, a heteroaryl ring having 5-10 ring atoms, or a

heterocyclyl ring having 3-10 ring atoms;

each R⁵ is independently selected from R, OR, CO₂R,

(CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,

CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;

each R⁶ is independently selected from R⁷, F, Cl,

5 (CH₂)_yN(R⁷)₂, N(R⁷)₂, OR⁷, SR⁷, NR⁷COR⁷, NR⁷CON(R⁷)₂,

CON(R⁷)₂, SO₂R⁷, NR⁷SO₂R⁷, COR⁷, CN, or SO₂N(R⁷)₂;


each R⁷ is independently selected from hydrogen or an
optionally substituted C₁₋₆ aliphatic group, or two R⁷
on the same nitrogen are taken together with the

10 nitrogen to form a 5-8 membered heterocyclyl or
heteroaryl ring;

R⁸ is selected from R, (CH₂)_wOR⁷, (CH₂)_wN(R⁴)₂, or (CH₂)_wSR⁷;
and

each w is independently selected from 0-4.




15 Examples of suitable Sp groups of formula I°
include pyrrole (a), imidazole (b), pyrazole (c),
triazole (d), oxazole (e), isoxazole (f), 1,3-thiazole
(g), 1,2-thiazole (h), furan (i), and thiophene (j), as
shown below:



20 wherein each of a through j is optionally substituted
with R⁶.

Accordingly, the present invention relates to
compounds of formula I° wherein Ring A is a pyridine
25 (II°), pyrimidine (III°), or triazine (IV°) ring as shown
below:

100021669 - 02080801



5

or a pharmaceutically acceptable derivative thereof,
wherein Sp , T_mR^1 , R^5 , U_nR^3 , and R^8 are as described above.

Preferred R^5 groups of formula I° are R or OR^7 .

10 Examples of such groups include OH , CH_2OH , carbocyclic, or
optionally substituted 5 or 6-membered aryl or heteroaryl
rings, such as phenyl, pyridyl, and cyclohexyl.
Preferred R^8 groups of formula I° are R and OR^7 , wherein R
is an optionally substituted group selected from C_{1-4}
15 aliphatic, 3-6 membered heterocyclic, or a 5-6 membered
aryl or heteroaryl ring. Examples of such groups include
phenyl, methyl, ethyl, OH , and CH_2OH . Preferred
substituents on the R^5 aryl or heteroaryl ring are
halogen, haloalkyl, OR° , and R° .

20 Preferred T_mR^1 groups of formula I° are
hydrogen, $\text{N}(\text{R}^4)_2$, OH , 3-6 membered carbocyclic, or an
optionally substituted group selected from C_{1-6} aliphatic
or a 5-6 membered aryl or heteroaryl ring. When R^1 is an
optionally substituted phenyl or aliphatic group,
25 preferred substituents on the phenyl or aliphatic group

are R⁷, halo, nitro, alkoxy, and amino. More preferred T_mR¹ groups are methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAc, NHC(O)NHCH₃, and CH₂NHCH₃. Most preferred T_mR¹ groups of formula I° are those listed in Table 1 below.

Preferred R³ groups of formula I° are hydrogen, carbocyclyl, -CH(R⁸)R, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and isopropyl. When R³ is optionally substituted phenyl, preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF₃, OH, SO₂NH₂, and methylene dioxy. When R³ is -CH(R⁹)R, examples of such groups include -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, and -CH(CH₂OH)CH₂cyclopropyl. Preferred U_n groups, when present, are -CH₂-, -O-, -NR⁷-, -NHCO-, and -NHCO₂-. More preferred U_nR³ groups of formula I° are those listed in Table 1 below.

Preferred compounds of formula I° are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

- (a) R³ is hydrogen, carbocyclyl, -CH(R⁸)R, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;
- (b) T_mR¹ is hydrogen, amino, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring; and

(c) R^5 is R or OR^7 , wherein R is carbocyclic, or an optionally substituted 5 or 6-membered aryl or heteroaryl ring.


More preferred compounds of formula I^o are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

(a) R^3 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, $-CH(CH_2OH)$ phenyl, $-CH(CH_2OH)$ ethyl, $-CH(CH_2OH)_2$, $-CH(CH_2OH)$ isopropyl, $-CH(CH_2OH)CH_2$ cyclopropyl, or an optionally substituted phenyl, benzyl, or isoxazolyl group;

(b) T_mR^1 is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH₂, NHCH₃, NHAc, NHC(O)NHCH₃, or CH_2NHCH_3 ; and

(c) R^5 is OH, CH_2OH , carbocyclic, or an optionally substituted phenyl or pyridyl ring.

A preferred embodiment relates to compounds of formula III-a:



III-a

25

or a pharmaceutically acceptable derivative thereof.

Preferred T_mR^1 groups of formula III-a are hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic

or a 5-6 membered aryl or heteroaryl ring. When R^1 is an optionally substituted phenyl or aliphatic group, preferred substituents on the phenyl or aliphatic group are R^7 , halo, nitro, alkoxy, and amino. Examples of such 5 preferred T_mR^1 groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, and CH_2NHCH_3 . More preferred T_mR^1 groups of formula III-a are those listed in Table 1 below.

Preferred R³ groups of formula III-a are

hydrogen, carbocyclyl, $-\text{CH}(\text{R}^8)\text{R}$, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and isopropyl. When R³ is optionally substituted phenyl, preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF₃, OH, SO₂NH₂, and methylene dioxy. When R³ is $-\text{CH}(\text{R}^8)\text{R}$, examples of such groups are -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, and -CH(CH₂OH)CH₂cyclopropyl. Preferred U_n groups, when present, are -CH₂-, -O-, -NR⁷-, -NHCO-, and -NHCO₂-.

More preferred U_nR³ groups of formula III-a are those listed in Table 1 below.

When R² is R⁵, preferred R⁵ groups are pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, wherein each group is optionally substituted. When R² is (CH₂)_yR⁵, (CH₂)_yCH(R⁵)₂, or -N(R⁴)₂, preferred R⁵ groups are pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, benzyl, -CH₂OH, -(CH₂)₂OH, and isopropyl, wherein each group is optionally substituted.

substituted. Preferred substituents on R⁵ are -OH, pyridyl, piperidinyl, and optionally substituted phenyl. When R² is -(CH₂)_yCH(R⁸)CH(R⁵)₂, preferred R⁸ groups are R⁷ and OR⁷ such as OH and CH₂OH. More preferred -QR² groups 5 are those listed in Table 1 below.

Preferred compounds of formula III-a are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

10 (a) R³ is hydrogen, carbocyclyl, -CH(R⁸)R, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;

15 (b) T_mR¹ is hydrogen, N(R⁴)₂, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring;

(c) Q is -CO-, -CO₂-, -CONH-, -SO₂-, -SO₂NH-, -OC(O)NH-, -C(O)ONH-, or -CONHNH-;

20 (d) R² is -NR⁴(CH₂)_yN(R⁴)₂, -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂, or -(CH₂)_yCH(R⁸)CH(R⁵)₂;

(f) R⁴ is R, R⁷, or -(CH₂)_yCH(R⁵)₂; and

(g) R⁵ is an optionally substituted group selected from phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl.

More preferred compounds of formula III-a are those having one or more, more preferably more than one, or most preferably all, of the features selected from the group consisting of:

30 (a) R³ is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or

an optionally substituted phenyl or benzyl group;


(b) $T_m R^1$ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , OH, NH_2 , NHCH_3 , NHAC , NHC(O)NHCH_3 , or CH_2NHCH_3 ;

(c) Q is -CO-, -CONH-, -SO₂-, or -SO₂NH-;

(d) R^2 is -(CH₂)_yR⁵, -(CH₂)_yCH(R⁵)₂, or -(CH₂)_yCH(R⁸)CH(R⁵)₂, wherein R⁸ is OH or CH₂OH; and

(e) R⁵ is -CH₂OH, -(CH₂)₂OH, isopropyl, or an optionally substituted group selected from pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl[1,4]diazepan-1-yl, 4-phenyl-piperazine-1-yl, pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, 1,2,3,4-tetrahydroisoquinoline, tetrahydrofuran-2-yl, cyclohexyl, phenyl, or benzyl.

Preferred compounds of formula III-a include
20 those of formula III-a':



25 or a pharmaceutically acceptable derivative thereof.

Preferred R⁵ groups of formula III-a' are optionally substituted 6-membered aryl, heteroaryl, and carbocyclic rings, such as phenyl, pyridyl, and cyclohexyl.

Preferred T_mR^1 groups of formula III-a' are hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C_{1-6} aliphatic or a 5-6 membered aryl or heteroaryl ring. When R^1 is an 5 optionally substituted phenyl or aliphatic group, preferred substituents on the phenyl or aliphatic group are R^7 , halo, nitro, alkoxy, and amino. Preferred T_mR^1 groups are methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH_2OCH_3 , CH_2OH , NH_2 , $NHCH_3$, $NHAc$, $NHC(O)NHCH_3$, 10 CH_2NHCH_3 , and those listed in Table 1 below.

Preferred R^3 groups of formula III-a' are hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4} aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or 15 heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and isopropyl. When R^3 is optionally substituted phenyl, preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, 20 Obenzyl, Ophenyl, OCF_3 , OH, SO_2NH_2 , and methylene dioxy. When R^3 is $-CH(R^8)R$, examples of such groups include $-CH(CH_2OH)phenyl$, $-CH(CH_2OH)ethyl$, $-CH(CH_2OH)_2$, $-CH(CH_2OH)isopropyl$, and $-CH(CH_2OH)CH_2cyclopropyl$. Preferred U_n groups, when present, are $-CH_2-$, $-O-$, $-NR^7-$, 25 $-NHCO-$, and $-NHCO_2-$. More preferred U_nR^3 of formula III-a' are those listed in Table 1 below.

Preferred compounds of formula III-a' are those having one or more, more preferably more than one, and most preferably all, of the features selected from the 30 group consisting of:

(a) R^3 is hydrogen, carbocyclyl, $-CH(R^8)R$, or an optionally substituted group selected from C_{1-4}

aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;

- (b) $T_m R^1$ is hydrogen, $N(R^4)_2$, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring; and
- (c) R^5 is an optionally substituted 6-membered aryl, heteroaryl, or carbocyclic ring.

More preferred compounds of formula III-a' are


10 those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

15 (a) R³ is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or an optionally substituted phenyl or benzyl group;

20 (b) T_mR¹ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃, or CH₂NHCH₃; and

(c) R⁵ is cyclohexyl or an optionally substituted phenyl or pyridylring.

25 Preferred compounds of formula III-a are further selected from those of formula III-a:



or a pharmaceutically acceptable derivative thereof.

Preferred R⁵ groups of formula III-a° are R or OR⁷. Examples of such groups include OH, CH₂OH, or

5 optionally substituted 6-membered aryl, heteroaryl, and carbocyclic rings, such as phenyl, pyridyl, and cyclohexyl. Preferred R⁸ groups of formula III-a° are R and OR⁷, wherein R is an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic,

10 or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include phenyl, methyl, ethyl, OH, and CH₂OH.

Preferred T_mR¹ groups of formula III-a° are hydrogen, N(R⁴)₂, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic

15 or a 5-6 membered aryl or heteroaryl ring. When R¹ is an optionally substituted phenyl or aliphatic group, preferred substituents on the phenyl or aliphatic group are R⁷, halo, nitro, alkoxy, and amino. Preferred T_mR¹ groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃, and CH₂NHCH₃. More preferred T_mR¹ groups of formula III-a° are those listed in Table 1 below.

Preferred R³ groups of formula III-a° are hydrogen, carbocyclyl, -CH(R⁸)R, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring. Examples of such groups include methyl, ethyl, propyl, cyclopropyl, cyclohexyl, benzyl, isoxazolyl, tetrahydrofuranyl, and isopropyl. When R³ is 25 optionally substituted phenyl, preferred substituents on the phenyl ring are halogen, alkyl, alkoxy, haloalkyl, Obenzyl, Ophenyl, OCF₃, OH, SO₂NH₂, and methylene dioxy. When R³ is -CH(R⁸)R, examples of such groups are

-CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂,
-CH(CH₂OH)isopropyl, and -CH(CH₂OH)CH₂cyclopropyl.

Preferred U_n groups, when present, are -CH₂-, -O-, -NR⁷-,
-NHCO-, and -NHCO₂-.

More preferred U_nR³ groups of
formula III-a° are those listed in Table 1 below.

Preferred compounds of formula III-a° are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

(a) R³ is hydrogen, carbocyclyl, -CH(R⁸)R, or an optionally substituted group selected from C₁₋₄ aliphatic, 3-6 membered heterocyclic, or a 5-6 membered aryl or heteroaryl ring;

(b) T_mR¹ is hydrogen, N(R⁴)₂, OH, 3-6 membered carbocyclyl, or an optionally substituted group selected from C₁₋₆ aliphatic or a 5-6 membered aryl or heteroaryl ring; and

(c) R⁵ is R or OR⁷, and R⁸ is R⁷ or OR⁷.

More preferred compounds of formula III-a° are those having one or more, more preferably more than one, and most preferably all, of the features selected from the group consisting of:

(a) R³ is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, isopropyl, -CH(CH₂OH)phenyl, -CH(CH₂OH)ethyl, -CH(CH₂OH)₂, -CH(CH₂OH)isopropyl, -CH(CH₂OH)CH₂cyclopropyl, or an optionally substituted phenyl or benzyl group;

(b) T_mR¹ is selected from optionally substituted phenyl, methyl, ethyl, propyl, cyclopropyl, cyclohexyl, CH₂OCH₃, CH₂OH, OH, NH₂, NHCH₃, NHAC, NHC(O)NHCH₃, or CH₂NHCH₃; and

(c) R⁵ is OH, CH₂OH, phenyl, pyridyl, or cyclohexyl,
and R⁸ is methyl, ethyl, OH, or CH₂OH.

Preferred compounds of formula III-a are set forth in Table 1 below. More preferred compounds in 5 Table 1 are those of formula III-a' or III-a^o.

Table 1^a. Compounds of Formula III-a













No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
1	H	phenyl	CON(Me) ₂
2	H	3-Cl-phenyl	CO(pyrrolidin-1-yl)
3	H	2-F-3-Cl-phenyl	CO(pyrrolidin-1-yl)
4	H	phenyl	CONH(CH ₂) ₂ pyridin-3-yl
5	H	phenyl	CO(morpholin-4-yl)
6	H	phenyl	
7	H	3,4-(CH ₃ O) ₂ -phenyl	
8	H	3,4-(CH ₃ O) ₂ -phenyl	
9	H	3-Me-phenyl	
10	H	2-F-3-Cl-phenyl	
11	H	3-Me-phenyl	
12	H	phenyl	
13	H	phenyl	
14	H	phenyl	
15	H	phenyl	

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
16	H	3,4-(CH ₃ O) ₂ - phenyl	CO(morpholin-4-yl)
17	H	3,4-(CH ₃ O) ₂ - phenyl	CONH(CH ₂) ₂ pyridin-3-yl
18	H	3-Me-phenyl	CO(morpholin-4-yl)
19	H	3-Me-phenyl	CONH(CH ₂) ₂ pyridin-3-yl
20	H	3-Cl-phenyl	CONH(CH ₂) ₂ pyridin-3-yl
21	H	3-Cl-phenyl	
22	H	3-Cl-phenyl	
23	H	3-Cl-phenyl	
24	H	3-Cl-phenyl	
25	H	3-Cl-phenyl	
26	H	2-F-3-Cl-phenyl	CO(morpholin-4-yl)
27	H	3-Cl-phenyl	CO(4-OH-piperidin-1-yl)
28	H	3-Cl-phenyl	
29	H	phenyl	CON(Me)CH ₂ Ph
30	H	phenyl	
31	H	phenyl	
32	H	phenyl	
33	H	3,4-(CH ₃ O) ₂ - phenyl	CON(Me)CH ₂ Ph
34	H	3,4-(CH ₃ O) ₂ - phenyl	
35	H	3,4-(CH ₃ O) ₂ - phenyl	
36	H	3-Me-phenyl	CON(Me)CH ₂ Ph










No. III-a-	$\mathbf{R}^3\mathbf{U}_n$	$\mathbf{T}_m\mathbf{R}^1$	$\mathbf{Q}\cdot\mathbf{R}^2$
37	H	3-Me-phenyl	
38	H	3-Me-phenyl	
39	H	3-Me-phenyl	
40	H	3-Cl-phenyl	$\text{CON}(\text{Me})\text{CH}_2\text{Ph}$
41	H	3-Cl-phenyl	
42	H	2-F-3-Cl-phenyl	$\text{CON}(\text{Me})\text{CH}_2\text{Ph}$
43	H	3-Cl-phenyl	
44	H	2-F-3-Cl-phenyl	
45	H	3-Me-phenyl	
46	H	3-Me-phenyl	
47	H	3-Me-phenyl	
48	H	3-Me-phenyl	
49	H	2-F-3-Cl-phenyl	
50	H	2-F-3-Cl-phenyl	

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
51	H	2-F-3-Cl-phenyl	
52	H	2-F-3-Cl-phenyl	
53	H	2-F-3-Cl-phenyl	
54	H	3-Cl-phenyl	
55	H	phenyl	
56	H	3,4-(CH ₃ O) ₂ - phenyl	
57	H	3,4-(CH ₃ O) ₂ - phenyl	
58	H	phenyl	
59	H	3-Cl-phenyl	CONH(CH ₂) ₂ pyridin-3-yl
60	H	3-Me-phenyl	
61	H	2-F-3-Cl-phenyl	
62	H	2-F-3-Cl-phenyl	
63	H	2-F-3-Cl-phenyl	

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
64	H	phenyl	
65	H	3,4-(CH ₃ O) ₂ - phenyl	
66	H	2-F-3-Cl-phenyl	
67	H	3,4-(CH ₃ O) ₂ - phenyl	
68	H	3-Cl-phenyl	
69	H	3-Me-phenyl	
70	H	3,4-(CH ₃ O) ₂ - phenyl	
71	H	phenyl	CO(pyrrolidin-1-yl)
72	H	3-Cl-phenyl	CO(morpholin-4-yl)
73	H	Methyl	CONHCH ₂ Ph
74	H	Methyl	CONHCH ₂ (3,4-F ₂ -phenyl)
75	H	Methyl	
76	H	Methyl	CONHCH ₂ (4-F-phenyl)
77	H	Methyl	CONHCH ₂ (3-Cl-phenyl)
78	H	Methyl	CONHCH ₂ (4-OMe-phenyl)
79	H	Methyl	CONHCH ₂ (3-Cl, 4-F-phenyl)
80	H	Methyl	
81	H	Methyl	
82	H	Methyl	

No. III-a	R^3U_n	T_mR^1	$Q-R^2$
83	H	Methyl	
84	H	NH ₂	
85	H	NHCH ₃	
86	H	NHC(O)CH ₃	
87	H	NHC(O)NHCH ₃	
88	H	OH	
89	H	CH ₂ NHCH ₃	
90	H	CH ₂ OH	
91	N-cyclohexyl	NHC(O)NHCH ₃	
92	C(O)CH ₃	NHC(O)NHCH ₃	
93	SO ₂ CH ₃	OH	
94	H	SO ₂ CH ₃	

J00716999 • 020302

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
95	H	CH ₂ OH	
96	cyclohexyl	CH ₃	
97	H	3,5-Cl ₂ -phenyl	CONHCH ₂ pyridin-4-yl
98	phenyl	3,5-Cl ₂ -phenyl	CONHCH ₂ (3-CF ₃ -phenyl)
99	H	3,5-Cl ₂ -phenyl	
100	H	3,5-Cl ₂ -phenyl	
101	H	3,5-Cl ₂ -phenyl	
102	H	3,5-Cl ₂ -phenyl	
103	phenyl	3,5-Cl ₂ -phenyl	
104	phenyl	3,5-Cl ₂ -phenyl	
105	H	3-F, 5-CF ₃ -phenyl	
106	H	n-propyl	CONH(CH ₂) ₂ pyridin-3-yl
107	H	methyl	CONH(CH ₂) ₂ pyridin-3-yl
108	methyl	methyl	CONH(CH ₂) ₂ pyridin-3-yl
109	methyl	H	CONH(CH ₂) ₂ pyridin-3-yl
110	ethyl	methyl	CONH(CH ₂) ₂ N(CH ₃) ₂
111	phenyl;	methyl	CONH(CH ₂) ₂ CH ₃
112	phenyl	methyl	CONH(CH ₂) ₃ phenyl













No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
113	ethyl	methyl	
114	ethyl	methyl	
115	ethyl	H	CONHCH ₂ (2-CF ₃ -phenyl)
116	phenyl	methyl	
117	ethyl	methyl	
118	ethyl	H	
119	phenyl	ethyl	CONHCH(CH ₃) ₂
120	phenyl	methyl	CONH(CH ₂) ₂ NH ₂
121	H	H	
122	H	H	
123	ethyl	methyl	
124	ethyl	methyl	CONH(CH ₂) ₃ phenyl
125	H	ethyl	
126	phenyl	methyl	
127	phenyl	methyl	

No. III-a-	R ³ U ⁿ	T _m R ¹	Q-R ²
128	methyl	methyl	
129	methyl	methyl	
130	phenyl	methyl	
131	H	methyl	
132	(CH ₂) ₂ N(Et) ₂	methyl	
133		methyl	
134	methyl	methyl	
135	phenyl	methyl	
136	3-F-phenyl	methyl	
137	3-OMe-phenyl	methyl	
138	3-OH-phenyl	methyl	
139		methyl	

No. III-a-	R^3U_n	T_mR^1	$\text{Q}\text{-R}^2$
140	4-SO ₂ NH ₂ -phenyl	methyl	
141	3-OBn-phenyl	methyl	
142		methyl	
143	phenyl	cyclohexyl	
144	phenyl	cyclopropyl	
145	phenyl	methyl	
146	phenyl	methyl	
147	3-F-phenyl	methyl	
148	3-F-phenyl	methyl	
149	3-ClF ₃ -phenyl	methyl	
150	CH ₂ phenyl	methyl	
151	3,4-Me ₂ -phenyl	methyl	

No. III-a-	R^3U_n	T_mR^1	$\text{Q}\text{-R}^2$
152	4-OBn-phenyl	methyl	
153	$\text{CH}(\text{CH}_3)_2$	methyl	
154	CH_2CF_3	methyl	
155		methyl	
156	2-OMe-phenyl	methyl	
157	4-OCF ₃ -phenyl	methyl	
158	$\text{CH}_2\text{CH}(\text{CH}_3)_2$	methyl	
159	$\text{CH}_2\text{cyclopropyl}$	methyl	
160	phenyl	CH_2OCH_3	
161	H	CH_2OCH_3	
162	cyclopropyl	methyl	
163	$(\text{CH}_2)_2\text{CH}_3$	methyl	












No. III-a-	R^3U_n	T_mR^1	$Q \cdot R^2$
164	phenyl	CH_2OCH_3	
165	phenyl	CH_2OH	
166		methyl	
167	ethyl	methyl	
168	ethyl	methyl	
169	ethyl	methyl	
170	ethyl	methyl	
171	ethyl	methyl	
172	ethyl	methyl	
173	ethyl	methyl	
174		methyl	
175	CH_2CH_2OH	methyl	

No. III-a-	R^3U_n	T_mR^1	$\text{Q}\text{-R}^2$
176		methyl	
177		methyl	
178		methyl	
179		methyl	
180	H	H	
181	H	H	
182	H	H	
183	H	H	
184	ethyl	methyl	
185	H	H	
186	H	H	
187	ethyl	CH_2OCH_3	








No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
188	ethyl	methyl	
189	ethyl	CH ₂ OH	
190	ethyl	methyl	
191	ethyl	methyl	
192	ethyl	methyl	
193		methyl	
194	2,3-Me ₂ -phenyl	methyl	
195	OCH ₂ CH ₃	methyl	
196		methyl	
197	ethyl	methyl	
198	ethyl	methyl	

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
199	3-fluorophenyl	methyl	
200	2-Cl-phenyl	methyl	
201		methyl	
202	cyclopropyl	methyl	
203	cyclopropyl	methyl	
204	cyclopropyl	methyl	
205	cyclopropyl	methyl	
206	O-Me	methyl	
207	O-isopropyl	methyl	
208	3-N(Me) ₂ -phenyl	methyl	
209	2-OH-phenyl	methyl	

No. III-a-	R^3U_n	T_mR^1	$\text{Q}\cdot\text{R}^2$
210		methyl	
211	2,3-Me ₂ -phenyl	methyl	
212	3-fluoro-phenyl	methyl	
213	acetyl	methyl	
214	2-Me-phenyl	methyl	
215	pyridin-3-yl	methyl	
216		methyl	
217		methyl	
218	NC(O)OEt	methyl	
219	CH ₂ pyridin-3-yl	methyl	
220		methyl	

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
221	isoxazol-3-yl	methyl	
222		methyl	
223	2-Me-phenyl	methyl	
224	2-Me-phenyl	methyl	
225	O(CH ₂) ₂ OH	methyl	
226	N(Me) ₂	methyl	
227	2-CF ₃ -phenyl	methyl	
228		methyl	
229		methyl	
230		methyl	
231	phenyl	methyl	


10071699-020802

No. III-a-	R ³ U _n	T _m R ¹	Q-R ²
232		methyl	
233		methyl	
234		methyl	
235		methyl	
236		methyl	
237		methyl	
238	CN	methyl	


^a Compound names for the compounds of formula III-a shown above in Table 1 are set forth in Appendix A.

The above formula III-a compounds are those
5 wherein Ring A is a pyrimidine ring and Sp is a pyrrole
ring. Inhibitors of formula I wherein Ring A is a
pyridine, pyrimidine, or triazine ring having the other
Sp rings shown above are otherwise structurally similar
to the formula III-a compounds and are represented by the
10 following general formulae II-b through II-j, III-b
through III-j, and IV-b through IV-j shown below in Table
2:

Table 2




15



II-e

III-e


IV-e



II-e'

III-e'


IV-e'



II-f

III-f

IV-f



II-g





III-g

IV-g

10071595 · 020802

5


10



10071899-0208024

5


10



II-i'

III-i'

IV-i'




II-j

III-j

IV-j

5



II-j'

III-j'

IV-j'

10 The compounds shown above in Table 2 are
structurally similar to compounds of formula III-a where
the pyrrole ring of formula III-a is replaced by each of
the following Sp rings: imidazole (b), pyrazole (c),
triazole (d), oxazole (e), isoxazole (f), 1,3-thiazole
15 (g), 1,2-thiazole (h), furan (i), and thiophene (j).
Accordingly, preferred QR², T_mR¹, and U_nR³ groups of the
compounds shown above in Table 2 are as described above
for the formula III-a compounds.

20 In another embodiment, this invention provides
a pharmaceutically acceptable composition comprising a

compound shown above in Table 2 and a pharmaceutically acceptable carrier.

Another aspect of this invention relates to a method of treating or preventing an ERK2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound shown above in Table 2 or a pharmaceutically acceptable composition comprising said compound.

10 Another aspect of this invention relates to a method of inhibiting ERK2 activity in a patient, which method comprises administering to the patient a compound shown above in Table 2 or a pharmaceutically acceptable composition comprising said compound.

15 Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound shown above in Table 2 or a pharmaceutically acceptable comprising said compound.

20 Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound shown above in Table 2 or a pharmaceutically acceptable composition comprising said compound.

25 Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease, which method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound shown above in Table 2 or a pharmaceutically acceptable comprising said compound.

30 One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering

10077699 - 20200225

blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound shown above in Table 2 or a pharmaceutically acceptable
5 composition comprising said compound. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's
10 disease. Another method relates to inhibiting the phosphorylation of β -catenin, which is useful for treating schizophrenia.

Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which
15 method comprises administering to the patient a compound shown above in Table 2 or a pharmaceutically acceptable composition comprising said compound.


Another method relates to inhibiting ERK2, Aurora-2, or GSK-3 activity in a biological sample, which
20 method comprises contacting the biological sample with a compound shown above in Table 2, or a pharmaceutically acceptable composition thereof, in an amount effective to inhibit ERK2, Aurora-2, or GSK-3.

Each of the aforementioned methods directed to
25 the inhibition of ERK2, Aurora-2 or GSK-3, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound shown above in Table 2, as described above.

The present compounds may be prepared in
30 general by methods known to those skilled in the art for analogous compounds, as illustrated by the general Schemes I through XII and the synthetic examples shown below.

100074595-02-000802

Scheme I



Reagents and conditions: (a) $T_mR^1CH_2COCl$, $AlCl_3$, CH_2Cl_2 , 2 hours, RT; (b) DMF , 24 hrs, room temperature; (c) $(Me_2N)_2-$
-
 $CHOT-Bu$, THF , 24 hrs, room temperature; (d) guanidine, $EtOH$, 12 hours, reflux; (e) thiourea, $EtOH$, K_2CO_3 , 12 hrs reflux; (f) $m-CPBA$, $EtOH$; (g) $U_nR^3-NH_2$, $DMSO$, $130^\circ C$.

Scheme I above shows a general synthetic route that is used for preparing the pyrrol-3-yl compounds of formula III-a of this invention when R^2 is an optionally substituted phenyl group or aliphatic group. In step (a), an optionally substituted acid chloride is combined with compound 1, dichloromethane, and aluminum trichloride to form compound 2. In cases where benzoyl acid chlorides are used, a wide variety of substituents on the phenyl ring are amenable to this reaction. Aliphatic acid chlorides are also used in many cases.

Examples of suitable R² groups include, but are not limited to, those set forth in Table 1 above.

The formation of amide 4 is achieved by treating compound 2 with an amine 3 in DMF. When amine 3 is a primary amine, the reaction proceeds at ambient temperature. When amine 3 is a secondary amine, the reaction is heated at 50°C to achieve complete reaction and afford amide 4.

The formation of enamine 5 at step (c) is achieved by treating amide 4 with (Me₂N)₂-CHOT-Bu at ambient temperature. Alternatively, the reaction to form enamine 5 at step (c) is also achieved by using dimethylformamide-dimethylacetal (DMF-DMA). The reaction using DMF-DMA typically requires elevated temperature to afford enamine 5 whereas using (Me₂N)₂-OtBu has the advantage of proceeding at ambient temperature to afford the enamine 5 in higher purity.


The formation of the pyrimidine compound 6 at step (d) is achieved by the treatment of enamine 5 with guanidine at elevated temperature. Alternatively, use of a substituted guanidine results in an amino substituent as is illustrated by 8.

As an alternative method, in step (e) intermediate 5 may be cyclized with S-methyl thiourea to form the 2-thiomethylpyrimidine 7 which may in turn be oxidized with m-CPBA to the sulfone. The sulfonyl group may be subsequently displaced by an amine to generate the substituted aminopyrimidine 8.

The compounds of formula III-a synthesized by this method, as exemplified in Table 1, were isolated by preparatory HPLC (reverse phase, 10→90% MeCN in water

over 15 minutes). The details of the conditions used for producing these compounds are set forth in the Examples.


Scheme II



Reagents and conditions: (a) K₂CO₃, DMA, 100°C.

Scheme II above shows a general method for preparing compounds 8 from intermediate 5 and an *N*-substituted guanidine (9). Intermediate 5 may be prepared according to Scheme I steps (a), (b), and (c) shown above. Compound 5 is treated with *N*-substituted guanidine (9) and potassium carbonate in dimethylacetamide to form compound 8. This reaction is amenable to a variety of *N*-substituted guanidines to form compounds of formula III-a. The details of the conditions used for producing these compounds are set forth in the Examples.


Scheme III



Reagents and conditions: (a) AlCl_3 neat, RT; (b) DMF, 24 hrs, room temperature; (c) polyphosphoric acid, 1 hour, 5 25-140°C; (d) POCl_3 , DMF, reflux; (e) $\text{NH}_2\text{-U}_n\text{R}^3$, iPrOH, reflux.

Scheme III above shows a general synthetic route that may be used for preparing the pyrrol-3-yl compounds of formula II-a of this invention. The 10 conversion of intermediate 5 to product 8 may be achieved through steps (c), (d), and (e) according to the method described in JACS, 1957, pp 79.

Scheme IV




Reagents and conditions: (a) MeOH, pyridine, Cl₂; (b) guanidine; (c) bromine, acetic acid; (d) NaCN, DMF; (e) 6, polyphosphoric acid, 1 hour, 25-140°C; (f) POCl₃, DMF, reflux; (g) NH₂-U_nR³, iPrOH, reflux; (h) SeO₂; (i) MeNH.

5

Scheme IV above shows a general synthetic route that may be used for preparing the imidazol-4-yl compounds of formula II-b of this invention. The conversion of intermediate 5 to product 8 may be achieved 10 through steps (e), (f), and (g) according to the method described in JACS, 1957, pp 79.


Scheme V



Reagents and conditions: (a) MeOH, pyridine, Cl₂; (b) 3; 15 (c) bromine, acetic acid; (d) NaCN, DMF; (e) 6, polyphosphoric acid, 1 hour, 25-140°C; (f) POCl₃, DMF, reflux; (g) NH₂-U_nR³, iPrOH, reflux.


Scheme V above shows a general synthetic route 20 that may be used for preparing the imidazol-2-yl compounds of formula II-b' of this invention. The conversion of intermediate 5 to product 8 may be achieved through steps (e), (f), and (g) according to the method described in JACS, 1957, pp 79.

Scheme VI



Scheme VI above shows a general synthetic route that may be used for preparing the pyrazol-3-yl compounds of formula II-c of this invention. The conversion of intermediate 4 to product 7 may be achieved through steps (c), (d), and (e) according to the method described in JACS, 1957, pp 79.


Scheme VII



Reagents and conditions: (a) 1,1'-carbonyldiimidazole
5 (CDI), triethylamine, THF; (b) N-butyllithium, THF, -78°C;
(c) 6, polyphosphoric acid, 1 hour, 25-140°C; (d) POCl₃,
DMF, reflux; (e) NH₂-U_nR³, iPrOH, reflux.

Scheme VII above shows a general synthetic
10 route that may be used for preparing the oxazol-2-yl
compounds of formula II-e' of this invention. The
conversion of intermediate 5 to product 8 may be achieved
through steps (c), (d), and (e) according to the method
described in JACS, 1957, pp 79.

15 Scheme VIII




Reagents and conditions: (a) N-butyllithium, TMEDA,

-78°C (b) t-butylolithium, THF, -78°C (c) 6, polyphosphoric acid, 1 hour, 25-140°C (d) POCl₃, DMF, reflux (e) NH₂-R, iPrOH, reflux.

5 Scheme VIII above shows a general synthetic route that may be used for preparing the thiazol-2-yl compounds of formula II-g' of this invention. The conversion of intermediate 5 to product 8 may be achieved through steps (c), (d), and (e) according to the method
10 described in JACS, 1957, pp 79.


Scheme IX



15 Reagents and conditions: (a) N-butyllithium, Bu₃SnCl;
Reagents and conditions: (a) N-butyllithium, Bu₃SnCl;
15 (b) t-butylolithium, THF, -78°C; (c) MeOCO₂Me; (d) 4,
Pd(0); (e) 6, polyphosphoric acid, 1 hour, 25-140°C; (f)
POCl₃, DMF, reflux; (g) NH₂-U_nR³, iPrOH, reflux.

20 Scheme IX above shows a general synthetic route that may be used for preparing the thiazol-4-yl compounds of formula II-g of this invention. The conversion of intermediate 5 to product 8 may be achieved through steps (e), (f), and (g) according to the method described in JACS, 1957, pp 79.

Scheme X



Reagents and conditions: (a) $\text{CH}_3\text{OCH}_2\text{CH}_2\text{COCl}$, AlCl_3 , CH_2Cl_2 , 2.5 hours, RT; (b) DMF, 24 hrs, room temperature; (c) $(\text{Me}_2\text{N})_2\text{-CHOT-Bu}$, THF, 24 hrs, room temperature; (d) N -substituted guanidine, EtOH, 12 hours, reflux; (e) BBr_3 , CH_2Cl_2 , Na_2CO_3 .

Scheme X above shows a general synthetic route
10 that is used for preparing compounds of formula **III-a**
where T_mR^1 is methoxymethyl or hydroxymethyl. In step
(a), 3-methoxypropionyl chloride is combined with
compound 1, dichloromethane, and aluminum trichloride to
form compound 2.


15 The formation of amide 4 is achieved by
treating compound 2 with an amine 3 in DMF. When amine 3
is a primary amine, the reaction proceeds at ambient
temperature. When amine 3 was a secondary amine, the
reaction is heated at 50°C to achieve complete reaction
20 and afford amide 4. The formation of enamine 5 at step
(c) is achieved by treating amide 4 with $(\text{Me}_2\text{N})_2\text{-CHOT-Bu}$
at ambient temperature.

The formation of the pyrimidine compound 6 at
step (d) is achieved by the treatment of enamine 5 with a
25 guanidine at elevated temperature. Alternatively, use of
a substituted guanidine results in an amino substituent.

10071699-026802

To form compounds where T_mR^1 is hydroxymethyl, intermediate 6 may be treated with BBr_3 in dichloromethane to form compounds 7. One of skill in the art would recognize that the hydroxymethyl group of compound 7 could be further derivatized to form a variety of compounds of formula **III-a**. The details of the conditions used for producing these compounds are set forth in the Examples.


10 Scheme XI



Reagents and conditions: (a) R^2NH_2 , MeCN, $0^\circ C$ to $25^\circ C$, 12 hours; (b) $AlCl_3$, CH_2Cl_2 , $25^\circ C$; (c) $MeOH:H_2O$ (2:1), $37^\circ C$.

15 Scheme XI above shows a general method for preparing the triazine compounds of formula **IV-a**. Step (a) is performed in the manner described at Scheme I, step (b) above. Step (b) is performed in the manner described at Scheme I, step (a) above. The formation of 20 the triazine ring at step (c) may be performed according to the methods described by Hirsch, J.; Petrakova, E.; Feather, M. S.; *J Carbohydr Chem* [JCACDM] 1995, 14 (8), 1179-1186. Alternatively, step (c) may be performed according to the methods described by Siddiqui, A. U.; 25 Satyanarayana, Y.; Rao, U. M.; Siddiqui, A. H.; *J Chem Res, Synop* [JRPSDC] 1995 (2), 43.

Scheme XII



Reagents and conditions: (a) K_2CO_3 , DMA, 100°C , 24 hrs.

5

Using the preparation of compound III-a-226 to illustrate, Scheme XII above shows a general synthetic route that is used for preparing compounds of formula III-a where U_n is NR^7 . The formation of the pyrimidine compound III-a-226 at step (a) is achieved by the treatment of enamine 5 with a guanidine 6 at elevated temperature. Alternatively, use of a substituted amino guanidine results in an hydrazyno substituent.

In another embodiment, this invention provides a pharmaceutically acceptable composition comprising a compound of formula I', I'', I°, III-a, III-a', or III-a°, and a pharmaceutically acceptable carrier.

Another aspect of this invention relates to a method of treating or preventing an ERK2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of compound of formula I', I'', I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a method of inhibiting ERK2 activity in a patient, which method comprises administering to the patient compound of

10071599.0200202

formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a
5 method of treating or preventing an Aurora-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable
10 composition comprising said compound.

Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula I', I", I°, III-a, III-a', or III-a°,
15 or a pharmaceutically acceptable composition comprising said compound.

Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease, which method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable
20 composition comprising said compound.

One aspect of this invention relates to a
25 method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a
30 pharmaceutically acceptable composition comprising said compound. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is

useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β -catenin, which is useful for treating schizophrenia.

5 Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said
10 compound.

Another aspect of this invention relates to a method of treating or preventing a CDK-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound.

The term "CDK-2-mediated condition" or "disease", as used herein, means any disease or other deleterious condition in which CDK-2 is known to play a role. The term "CDK-2-mediated condition" or "disease" also means those diseases or conditions that are alleviated by treatment with a CDK-2 inhibitor. Such conditions include, without limitation, cancer,
20 Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. See Fischer, P.M. and Lane, D.P., *Current Medicinal Chemistry*, 7, 1213-1245
25 (2000); Mani, S., Wang, C., Wu, K., Francis, R. and Pestell, R., *Exp. Opin. Invest. Drugs*, 9, 1849 (2000);
30 Fry, D.W. and Garrett, M.D., *Current Opinion in*

2025 2020 1999 2002

Oncologic, Endocrine & Metabolic Investigational Drugs,
2, 40-59 (2000).

Another aspect of this invention relates to a method of treating or preventing a Lck-mediated disease,
5 which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound.

10 The terms "Lck-mediated disease" or "Lck-mediated condition", as used herein, mean any disease state or other deleterious condition in which Lck is known to play a role. The terms "Lck-mediated disease" or "Lck-mediated condition" also mean those diseases or
15 conditions that are alleviated by treatment with an Lck inhibitor. Lck-mediated diseases or conditions include, but are not limited to, autoimmune diseases such as transplant rejection, allergies, rheumatoid arthritis, and leukemia. The association of Lck with various
20 diseases has been described [Molina et al., *Nature*, 357, 161 (1992)].

Another aspect of this invention relates to a method of treating or preventing an AKT3-mediated disease, which method comprises administering to a
25 patient in need of such a treatment a therapeutically effective amount of a compound of formula I', I", I°, III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound.

The terms "AKT3-mediated disease" or "AKT3-mediated condition", as used herein, mean any disease state or other deleterious condition in which AKT3 is known to play a role. The terms "AKT3-mediated disease" or "AKT3-mediated condition" also mean those diseases or

10274559 - 020802

conditions that are alleviated by treatment with an AKT inhibitor. AKT3-mediated diseases or conditions include, but are not limited to, proliferative disorders, cancer, and neurodegenerative disorders. The association of AKT3
5 with various diseases has been described [Zang, Q. Y., et al, *Oncogene*, 19 (2000)] and [Kazuhiko, N., et al, *The Journal of Neuroscience*, 20 (2000)].

Another method relates to inhibiting ERK2, Aurora-2, CDK-2, Lck, AKT3, or GSK-3 activity in a
10 biological sample, which method comprises contacting the biological sample with a compound of formula I', I'', I°,
III-a, III-a', or III-a°, or a pharmaceutically acceptable composition comprising said compound, in an amount effective to inhibit ERK2, Aurora-2, CDK-2, Lck,
15 AKT3, or GSK-3.

Each of the aforementioned methods directed to the inhibition of ERK2, Aurora-2, CDK-2, Lck, AKT3, or GSK-3, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of
20 formula I', I'', I°, III-a, III-a', or III-a°, as described above. More preferably, each of the aforementioned methods is carried out with a preferred compound of formula I', I'', I°, III-a', or III-a°, and most preferably with a compound of formula I'', I°, III-a', or III-a°.

25 In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

30


SYNTHETIC EXAMPLES

For compounds where the HPLC Method is designated as "A", the following method was utilized: a

2007/07/26 10:59:59 - 020806


gradient of water:MeCN, 0.1% TFA (95:5 → 0:100) was run over 22 minutes at 1 mL/min and 214 nm. For compounds where the HPLC Method is designated as "B", the following method was utilized: a gradient of water:MeCN, 0.1% TFA (90:10 → 0:100) was run over 8 minutes at 1 mL/min and 214 nm. Each of methods A and B utilize the YMC ODS-AQ 55 120A column with a size of 3.0 x 150 mm. As used herein, the term " R_t " refers to the retention time, in minutes, associated with the compound using the designated HPLC method.

Example 1



2,2,2-Trichloro-1-(4-phenyl acetyl-1H-pyrrol-2-yl)-ethanone (1): In a dry flask, phenylacetyl chloride (1 equivalent) was combined with 2-trichloroacetyl pyrrole (1 equivalent) in a minimum amount of dichloromethane (DCM) to dissolve the reactants. To the resulting solution, at ambient temperature, was added aluminum trichloride (1 equivalent). After 2 hours, the reaction mixture was applied directly onto a silica gel column. Gradient elution with 10% ethyl acetate to 50% ethyl acetate in hexanes provided compound 1 in 60% yield. ^1H NMR (CDCl_3) δ 4.0 (s, 2H), 7.1-7.35 (m, 7H), 9.7 (br s, NH). HPLC using method B provided R_t of 4.9 minutes. LC/MS ($M+1$) 330.2, ($M-1$) 328.1.


Example 2



2,2,2-Trichloro-1-(4-(3-Chlorophenyl) acetyl-1H-pyrrol-2-yl)-ethanone (2): In a dry flask, 3-chlorophenylacetyl chloride (1 equivalent) was combined with 2-trichloroacetyl pyrrole (1 equivalent) in a minimum amount of dichloromethane (DCM). To the resulting solution, at ambient temperature, was added aluminum trichloride (1 equivalent). After 2 hours, the reaction mixture was applied directly onto a silica gel column. Gradient elution with 10% ethyl acetate to 50% ethyl acetate in hexanes provided compound 2. HPLC using method A provided R_t of 15 minutes

15


Example 3



1-[5-(2,2,2-Trichloro-acetyl)-1H-pyrrol-3-yl]-propan-1-one (3): In a dry flask, 3-propionyl chloride (1 equivalent) was combined with 2-trichloroacetyl pyrrole (1 equivalent) in a minimum amount of dichloromethane (DCM). To the resulting solution, at ambient temperature, was added aluminum trichloride (1 equivalent). After 2 hours, the reaction mixture was applied directly onto a silica gel column. Gradient elution with 10% ethyl acetate to 50% ethyl acetate in hexanes provided compound 3

10071599-020802


Example 4



4-Phenylacetyl-1*H*-pyrrole-2-carboxylic acid benzylamide

(4): To a solution of compound 1 (1 equivalent) in DMF, at ambient temperature, was added benzylamine (1.2 equivalents). After 24 hours, the solvent was evaporated and the crude product 4 was used without purification. HPLC using method B provided R_t of 3.8 minutes. FIA/MS 10 ($M+1$) 319.3, ($M-1$) 317.2.


Example 5



2-(3-Chlorophenyl)-1-[5-(morpholine-4-carbonyl)-1*H*-pyrrol-3-yl]-ethanone (5)


To a solution of compound 2 (1 equivalent) in DMF, at ambient temperature, was added morpholine (1.2 equivalents). After 24 hours, the solvent was evaporated and the crude product 5 was used without purification. FIA/MS ($M+1$) 333.3, ($M-1$) 331.2. 20 ^1H NMR was consistent with expected structure..

Example 6




4-Propionyl-1*H*-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide (6): To a solution of compound 3 (1 equivalent) in DMF, at ambient temperature, was added 3,4-difluorobenzyl amine (1.2 equivalents). After 24 hours, the solvent was evaporated and the crude product 6 was used without purification.

Example 7



10 4-(3-Dimethylamino-2-phenyl-acryloyl)-1*H*-pyrrole-2-carboxylic acid benzylamide (7): To a solution of compound 4 (1 equivalent) in THF, at ambient temperature, was added (Me_2N) $_2\text{CHOT-Bu}$ (3 equivalents). After 24 hours, the solvent was evaporated and the crude product 7 was used without purification. ^1H NMR (CDCl_3) δ 4.4 (s, 2H), 4.8 (s, NH), 6.8-7.4 (m, 13H).


Example 8



20 2-(3-Chloro-phenyl)-3-dimethylamino-1-[5-(morpholine-4-carbonyl)-1*H*-pyrrol-3-yl]-propenone (8): To a solution of compound 5 (1 equivalent) in THF, at ambient temperature, was added (Me_2N) $_2\text{CHOT-Bu}$ (3 equivalents). After 24 hours, the solvent was evaporated and the crude product 8 was

used without purification. HPLC using method B provided R_t of 11.2 minutes.

Example 9




5

III-a-74

4-(2-Amino-5-methyl-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide (III-a-74):

Step 1: To a solution of compound 6 (1 equivalent) in 10 THF, at ambient temperature, was added $(\text{Me}_2\text{N})_2\text{CHOT-Bu}$ (3 equivalents). After 24 hours, the solvent was evaporated and the crude product was utilized without purification. Step 2: To a solution of the compound formed above at Step 1 (1 equivalent) in ethanol, at ambient temperature, 15 was added guanidine (3 equivalents) and the resulting mixture heated at reflux. After 12 hours, the solvent was evaporated and the crude product purified by preparatory HPLC (reverse phase; 10 \rightarrow 90% MeCN in water; 15 minutes) to afford the desired compound III-a-74. HPLC 20 using method B provided R_t of 7.9 minutes. ^1H NMR was consistent with expected structure. FIA/MS Obs. M+1 /M-1.

Example 10




25

III-a-72

{4-[2-Amino-5-(3-chlorophenyl)-pyrimidine-4-yl]-1*H*-pyrrol-2-yl}-morpholin-4-yl-methanone (**III-a-72**): To a solution of compound **8** (1 equivalent) in ethanol, at ambient temperature, was added guanidine (3 equivalents)

5 and the resulting mixture heated at reflux. After 12 hours, the solvent was evaporated and the crude product purified by preparatory HPLC (reverse phase; 10→90% MeCN in water; 15 minutes) to afford the desired compound **III-a-72**. HPLC using method B, R_t =7.9 minutes. ^1H NMR was
10 consistent with expected structure. FIA/MS Obs. ($M+1$) 384.4 amu.


Example 11



15 **N-(2-Hydroxy-1-(S)-phenyl-ethyl)-guanidine·HCl:** (*S*) - Phenylglycinol (0.38g, 2.7 mmol) and bis-Boc guanidine-*(N*)-triflate (0.9g, 2.3 mmol) were combined in methylene chloride (anhydrous, 5mL) and stirred at ambient temperature overnight. Completion of the reaction was
20 verified by HPLC. The mixture was diluted with ethyl acetate, washed with 2M sodium bisulfite, brine then dried over MgSO₄, filtered and concentrated *in vacuo*. The bis-Boc guanidine intermediate was treated with 4N HCl/dioxane (5mL) and stirred at room temperature until
25 deprotection was complete (48 h) to afford the title compound..

100-455700-2


Example 12



III-a-155

4- [2- (2-Hydroxy-1- (*S*) -phenyl-ethylamino) -5-methyl-
5 pyrimidin-4-yl]-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-
1- (*S*) -phenyl-ethyl)-amide (III-a-155): 4- (3-
Dimethylamino-2-methyl-acryloyl)-1*H*-pyrrole-2-carboxylic
acid (2-hydroxy-1-phenyl-ethyl)-amide (100 mg, 0.29 mmol)
was combined with N- (*S*) -phenylglycinol guanidine•HCl (126
10 mg) and potassium carbonate (121 mg) in N,N-
dimethylacetamide (2mL). The resulting suspension was
heated and stirred at 100° C for 24 hours. The crude
material was diluted with ethyl acetate, washed with
saturated NaHCO₃, brine, dried over MgSO₄ and concentrated
15 in vacuo. Purification by prep HPLC (Gilson: Column =
CombiHT SB-C189 5 μM 21.2 mm x 100 mm, eluent = 0.1%TFA
MeCN/H₂O gradient) followed by preparative TLC (silica,
5% MeOH in CH₂Cl₂) afforded compound III-a-155 as a pale
yellow solid (8.0 mg). HPLC Method B, R_t=4.76 minutes; MS
20 (FIA) 458.2 (M+1), 456.1 (M-1); ¹H NMR consistent with
structure.

Example 13




III-a-162

4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1*H*-
5 pyrrole-2-carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-
amide (III-a-162): 4-(3-Dimethylamino-2-methyl-acryloyl)-
1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-
amide (100 mg, 0.29 mmol) was combined with cyclopropyl
guanidine•HCl (80 mg) and potassium carbonate (121 mg) in
10 N,N-dimethylacetamide (2mL). The resulting suspension
was heated and stirred at 100°C for 24 hours. The crude
material was diluted with ethyl acetate, washed with
saturated NaHCO₃, and brine, dried over MgSO₄ then
concentrated *in vacuo*. Purification by preparative TLC
15 (silica, 1:1 EtOAc:Hexanes) afforded III-a-162 as a
yellow solid (7.8 mg). HPLC Method B, R_t=4.29 minutes;
LC/MS(m/z) 378.2 (M+1), 376.2 (M-1); ¹H NMR consistent
with structure.

20

Example 14




3-Methoxy-1-[5-(2,2,2-trichloro-acetyl)-1*H*-pyrrol-3-yl]-
propan-1-one: To a solution of 2-trichloroacetyl pyrrole

(1.0 equivalent, 4.67g, 22 mmol) in methylene chloride (5 mL) was added 3-methoxypropionyl chloride (1.0 equivalent, 22 mmol) then aluminium trichloride (1.0 equivalent, 2.93g, 22 mmol) was added in small portions.

5 After 2.5 hours, the crude mixture was chromatographed on silica gel (MeOH 2% in DCM) to afford 3.0 g of the Friedel-Craft product. ^1H NMR consistent with structure.


Example 15



10 **4-(3-Methoxy-propionyl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide:** To a solution of 3-methoxy-1-[5-(2,2,2-trichloro-acetyl)-1H-pyrrol-3-yl]-propan-1-one (3.0 g, 10 mmol) in acetonitrile (50 mL), cooled to 0°C, was added (S)-(+)-phenyl glycinol (1.2 equivalent, 1.65 g, 12 mmol) and the resulting mixture stirred for 3 days at room temperature. The solvent was removed under reduced pressure and the residue purified by chromatography on silica gel (MeOH 5% in DCM) to afford 5.3 g of the title compound as a white solid.
15 HPLC Method B, R_t =4.2 minutes; LC/MS(m/z) 317.03 (M+1), 315.00 (M-1); ^1H NMR consistent with structure.

20


Example 16



4-(3-Dimethylamino-2-methoxymethyl-acryloyl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide:

5 4-(3-Methoxy-propionyl)-1*H*-pyrrole-2-carboxylic acid (2-
hydroxy-1-(*S*)-phenyl-ethyl)-amide was treated with an
excess of Bredereck's reagent in THF at room temperature
to 50°C for 3 days. The solvent was removed under
reduced pressure and the concentrate was used directly in
10 the next step. HPLC Method B, R_t =5.0 minutes "broad
peak".

Example 17




III-a-164

4-(5-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (III-a-164): 4-(3-Dimethylamino-2-methoxymethyl-acryloyl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (0.27 mmol) was combined with phenyl guanidine (73 mg) in N,N-dimethylacetamide (2 mL) and the resulting suspension was heated at 90°C for 35 hours.

The reaction mixture was diluted with ethyl acetate, washed with saturated NaHCO₃ and brine, dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by prep HPLC (Gilson: Column = CombiHT SB-C189 5 μM, 21.2 mm x 100 mm, eluent = 0.1%TFA MeCN/H₂O gradient) to afford **III-a-164** as a yellow solid (3.2 mg). LC/MS (m/z) 444.16 (M+1), 442.19 (M-1); HPLC Method B, R_t=5.16 minutes: ¹H NMR consistent with structure.

10

Example 18




III-a-165

4-(5-Hydroxymethyl-2-phenylamino-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide (**III-a-165**): To a solution of **III-a-164** (15 mg, 0.03 mmol) in dichloromethane (2 mL), cooled to -78°C, was added BBr₃ (135 μL, 0.13 mmol). After 15 minutes the reaction was allowed to warm to room temperature. After 45 minutes, the reaction was quenched with a saturated solution of sodium carbonate and the resulting mixture was stirred for an additional 30 minutes before extraction with ethyl acetate. The organic layers were combined and washed with brine then dried over sodium sulfate. The crude mixture was purified by prep TLC (silica, 7% MeOH in CH₂Cl₂) to afford **III-a-165** as a beige solid (1.6 mg). HPLC Method B, R_t=4.54 minutes; LC/MS

2020US2574208 - 2020US2574208 - 2020US2574208

(m/z) 430.15 (M+1), 428.03 (M-1); ^1H NMR consistent with structure.


Example 19



4-(2-Amino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide (III-a-161): The enamine formed above at Example 16 (0.27 mmol)

10 was combined with guanidine•HCl (51 mg), and K_2CO_3 (100 mg) in N,N-dimethylacetamide (4 mL). The heterogenous mixture was heated and stirred at 90° C for 35 h. The crude material was diluted with ethyl acetate, washed with saturated NaHCO₃ and brine, dried (MgSO_4) and
15 concentrated *in vacuo*. Purification by prep HPLC (Gilson: Column = CombiHT SB-C18 5 μM , 21.2 mm x 100 mm, eluent = 0.1%TFA MeCN/H₂O gradient) afforded III-a-161 as a yellow solid (2.0 mg). LC/MS(m/z) 368.12 (M+1), 366.15 (M-1), R_t (HPLC) = 3.77 min, ^1H NMR consistent with
20 structure.


Example 20



4-(2-Mercapto-5-methyl-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide:
4-(3-Dimethylamino-2-methoxymethyl-acryloyl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide

5 (17.6 mmol, 6.0 g) was combined with thiourea (39 mmol, 3.0 g) and potassium carbonate (53 mmol, 7.3 g) in ethanol (50 mL) and the resulting suspension was heated at 90° C for 24 hrs. The solvent was removed *in vacuo* and the resulting black solid was diluted with water and the 10 solid was removed by filtration. The solid was washed with ethyl acetate twice and the aqueous solution was acidified to pH 5-6 with HCl(2N). The solid formed was removed by filtration and the aqueous solution was then extracted twice with ethyl acetate. The combined organic 15 phases were dried over sodium sulfate. The solvent was removed under vacuum to afford the title compound as a brown solid (3.0 g, 48% yield). HPLC Method B, R_t =3.7 minutes, ^1H NMR consistent with structure.


Example 21



20 4-(5-Methyl-2-propylsulfanyl-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide:
To a solution of 4-(2-mercaptop-5-methyl-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (7.7 mmol, 2.74 mmol) in aqueous ammonia (15%) was added at room temperature *n*-propyl iodide (11.6 mmol, 1.1 mL). The solution was stirred overnight at

room temperature. The resulting solid was collected by filtration and used directly for the next step. ^1H NMR consistent with the structure.

5




4-[5-Methyl-2-(propane-1-sulfonyl)-pyrimidin-4-yl]-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide: The thiopropyl compound (7.7 mmol, 3.05g) prepared

10 at Example 21 above was dissolved in 120 mL of ethanol. To this solution, maintained at room temperature, was added *m*-CPBA (70% w/w%, 23.1 mmol, 4.0 g). The solution was stirred for an additional 4 hours at room temperature. The solvent was removed *in vacuo* and the residue dissolved in ethyl acetate, then washed 4 times with a solution of sodium hydroxide (1N). The organic phase was dried over sodium sulfate and concentrated *in vacuo* to afford the title compound as a white solid (1.7g, 51% yield for 2 steps). HPLC Method B, R_t =5.4

15 minutes. ^1H NMR consistent with the structure.

20


Example 23



4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide: To a solution of 4-[5-methyl-2-(propane-1-sulfonyl)-pyrimidin-4-yl]-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (47 μ mol, 20 mg) in DMSO (1 mL) was added ethylamine (0.5 mmol, 150 μ L). The mixture was heated at 130°C for 24 hours to afford the title compound. LC/MS(m/z) 366.2 (M+1); HPLC Method B, R_t =4.2 minutes; 3 H NMR consistent with the structure.

10

Example 24




III-a-226

4-[2-(*N'*,*N'*-Dimethyl-hydrazino)-5-methyl-pyrimidin-4-yl]-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (III-a-226): To a solution of 4-(3-dimethylamino-2-methoxymethyl-acryloyl)-1*H*-pyrrole-2-carboxylic acid (2-hydroxy-1-(*S*)-phenyl-ethyl)-amide (0.15 mmol, 50 mg) in DMA (2 mL) was added dimethyl-N,N-aminoguanidine•2HCl (0.17 mmol, 30 mg) and potassium carbonate (0.36 mmol, 50 mg). The reaction mixture was stirred for 48 hrs at 100°C. The solvent was removed by hi-vacuum "GeneVac" and the residue purified by preparative HPLC (Gilson: Column = CombiHT SB-C189 5 μ M 21.2 mm x 100 mm, eluent = 0.1%TFA MeCN/H₂O gradient) followed by preparative TLC (silica, 5% MeOH in CH₂Cl₂)

"double elutions" afforded compound III-a-226 as a pale yellow solid (1.3 mg). HPLC Method B, R_t =4.03 min.; LC/MS (m/z) 381.1 (M+1), 379.1 (M-1); ^1H NMR consistent with structure.


5

Example 25



Ethanolguanidine: Ethanolamine hydrochloride (200 mg, 2 mmol) was added to a mixture of N, N'-di-boc -N''- triflylguanidine (800 mg, 2 mmol) and TEA (0.28 mL, 2 mmol) in dichloromethane (10 mL). The mixture was stirred overnight then diluted with EtOAc, washed with sodium bisulfate (2M), saturated sodium bicarbonate, dried over NaSO_4 and concentrated *in vacuo*. The crude residue was purified by flash column chromatography eluting with 20% CH_2Cl_2 /hexane to afford a white solid (0.56 g, 92%). ^1H NMR (CDCl_3): δ 4.18 (q, 2H), 1.60 (d, 18H), 1.37 (t, 3H). To this bis-Boc guanidine was added 4M HCl/dioxane (5 mL). The mixture was stirred for 24 h and then concentrated to afford the title compound (0.26 g). ^1H NMR (MeOD): δ 3.92 (q, 2H), 1.27 (t, 3H). MS (M+1) 104.

Example 26



25

III-a-195


4-(2-Ethanolamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-(s)-phenyl-ethyl)-amide

(III-a-195): To a mixture of 4-(3-dimethylamino-2-methyl-acryloyl)-1H-pyrrole-2-carboxylic acid (2-hydroxymethyl-

5 1-(S)-phenyl-ethyl) amide (0.1 mmol) and K₂CO₃ (55 mg, 0.4 mmol) in DMF (1 mL) was added ethanolguanidine hydrogen chloride (0.2 mmol). The resulting suspension was stirred for 6 hours at 90 °C. The reaction mixture was filtered and the filtrate concentrated in vacuo. The 10 crude residue was purified by preparative HPLC (Gilson: Column = CombiHT SB-C18 9 5 μM 21.2 mm x 100 mm, eluent = 0.1%TFA MeCN/H₂O gradient) to afford compound III-a-195 as yellow oil (21 mg). HPLC (method B) R_t = 4.08 min; MS (M+1) 382.1.

15


Example 27



Ethyl carbamate guanidine: Ethylcarbazate (208 mg, 2 mmol) was added to a solution of N'N'-di-boc N''-

20 triflylguanidine (800 mg, 2 mmol) in dichloromethane (10 mL). The mixture was stirred for overnight then diluted with EtOAc, washed with sodium bisulfat (2M), saturated sodium bicarbonate, dried over anhydrous NaSO₄ and concentrated in vacuo. The crude residue was purified by 25 flash column chromatography eluting with 30% EtOAc/hexane to afford a white solid (0.55g). To this bis-boc guanidine was added 4M HCl/Dioxane (5 mL). The mixture was stirred for 24 hours and then concentrated to afford the title compound. ¹H NMR (MeOD): δ 3.4.18 (d, 2H), 3.26 (s, 1H), 1.28 (t, 3H). MS (M+1) 134.

Example 28



III-a-218

4-(2-Ethyl carbamate-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
5 2-carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide
(III-a-218): To a mixture of 4-(3-dimethylamino-2-methyl-
acryloyl)-1H-pyrrole-2-carboxylic acid (2-hydroxymethyl-
1-(S)-phenyl-ethyl) amide (0.1 mmol) and K₂CO₃ (55 mg, 0.4
mmol) in DMF (1 mL) was added ethyl carbamate guanidine
10 hydrogen chloride (0.2 mmol). The resulting suspension
was stirred for 6 hours at 90 °C. The reaction mixture
was filtered and the filtrate was concentrated *in vacuo*.
The crude residue was purified by preparative HPLC
(Gilson: Column = CombiHT SB-C189 5 μM 21.2 mm x 100 mm,
15 eluent = 0.1%TFA MeCN/H₂O gradient) to afford compound
III-a-218 as a yellow oil (10 mg). HPLC (method B) R_t =
4.03; MS (M+1) 425.1. ¹H NMR (MeOD) 8.08 (s, 1H); 7.87 (s,
1H); 7.7 (s, 1H), 7.24-7.5 (m, 5H); 5.15 (t, 1H), 4.2 (m,
2H), 3.85 (m, 2H); 2.5 (s, 3H).

20

Example 29

We have prepared other compounds of formula
III-a by methods substantially similar to those described
in the above Examples 1-28 and those illustrated in
25 Schemes I-XII. The characterization data for these

compounds is summarized in Table 3 below and includes LC/MS, HPLC, and ^1H NMR data.

Where applicable, ^1H NMR data is summarized in Table 3 below wherein "Y" designates ^1H NMR data is available and was found to be consistant with structure. Compound numbers correspond to the compound numbers listed in Table 1.

Table 3. Characterization Data for Selected Compounds

Compound No III-a-	M+1	M-1	HPLC Method	R _t (min)	^1H NMR
122	352.17	-	-	-	-
136	432.2	429.8	B	5.53	-
137	444.3	442.3	B	5.00	-
138	430.2	428.3	B	4.47	Y
139	458.3	456.3	B	4.72	-
140	493.3	491.3	B	4.45	-
141	520.2	518.2	B	5.98	-
142	436.2	-	B	4.0	-
144	440.17	-	A	10.1	Y
145	446.2	444.1	B	5.45	-
146	482.2	-	B	5.69	-
147	464.2	-	B	5.87	-
148	500.1	-	B	6.12	-
149	482.2	480.4	B	6.11	-
150	428.2	426.2	B	5.13	-
153	380.2	378.2	B	4.63	Y
154	420.1	418.1	B	4.74	Y
155	458.2	456.1	B	4.76	Y
156	441.13	-	B	5.14	-
157	498.2	-	B	6.00	-
159	392.2	390.1	B	4.75	Y
162	378.2	376.2	B	4.29	Y
163	380.2	378.0	B	4.65	Y
180	338.15	-	B	3.8	-

Compound No III-a-	M+1	M-1	HPLC Method	R _t (min)	¹ H NMR
181	396.22	-	B	3.9	-
182	382.18	-	B	4.1	-
183	352.17	-	-	-	-
188	367.2	-	B	2.86	Y
190	453.1	-	B	5.86	Y
191	384.1	-	B	4.46	Y
192	384.1	-	B	4.41	Y
214	428.1	-	B	4.9	-
215	415.1	-	B	4.3	Y
216	422.1	-	B	4.43	Y
217	422.1	-	B	4.44	-
219	429.3	-	B	3.64	Y
221	405.19	-	B	4.5	-
227	482.4	-	B	5.5	-
229	419.03	-	B	4.29	Y
230	510.4	-	B	5.19	-
231	432.3	-	B	5.23	Y

BIOLOGICAL TESTING

The activity of the present compounds as protein kinase inhibitors may be assayed *in vitro*, *in vivo* or in a cell line. *In vitro* assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of the activated protein kinase. Alternate *in vitro* assays quantitate the ability of the inhibitor to bind to the protein kinase.

10 Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/protein kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with the protein kinase bound to known radioligands. The details

208059-020820

of the conditions used for performing these assays are set forth in Examples 30 through 37.

Example 30

ERK INHIBITION ASSAY

Compounds were assayed for the inhibition of ERK2 by a spectrophotometric coupled-enzyme assay (Fox et al (1998) *Protein Sci* 7, 2249). In this assay, a fixed concentration of activated ERK2 (10 nM) was incubated with various concentrations of the compound in DMSO (2.5 %) for 10 min. at 30°C in 0.1 M HEPES buffer, pH 7.5, containing 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200 μM NADH, 150 μg/mL pyruvate kinase, 50 μg/mL lactate dehydrogenase, and 200 μM erktide peptide. The reaction was initiated by the addition of 65 μM ATP. The rate of decrease of absorbance at 340 nm was monitored. The IC₅₀ was evaluated from the rate data as a function of inhibitor concentration.

Table 4 shows the results of the activity of selected compounds of this invention in the ERK2 inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having an activity designated as "A" provided a percent inhibition less than or equal to 33%; compounds having an activity designated as "B" provided a percent inhibition of between 24% and 66%; and compounds having an activity designated as "C" provided a percent inhibition of between 67% and 100%. Compounds having an activity designated as "D" provided a K_i of less than 0.1 micromolar; compounds having an activity designated as "E" provided a K_i of between 0.1 and 1.0 micromolar; and

10071699.020802

compounds having an activity designated as "F" provided a K_i of greater than 1.0 micromolar.

Table 4. ERK2 Inhibitory Activity of Selected Compounds

No. III-a-	Activity	No. III-a-	Activity	No. III-a-	Activity
2	B	3	A	4	A
5	A	6	A	7	A
8	A	9	A	10	A
11	A	12	B	13	A
14	B	15	A	16	A
17	A	18	A	19	A
20	A	21	B	22	A
23	C	24	A	25	A
26	A	27	A	28	A
29	C	30	A	31	A
32	A	33	A	34	B
35	B	36	B	37	C
39	C	40	C	41	A
42	C	43	A	44	C
45	B	46	A	47	C
48	B	49	A	50	A
51	A	52	A	53	A
54	A	55	A	56	A
57	A	58	A	59	A
60	A	61	A	62	C
63	A	64	A	65	A
66	A	67	A	68	A
69	A	70	A	71	A
72	B	100	A	101	A
102	A	103	F	104	A
105	E	107	F	111	D

No. III-a-	Activity	No. III-a-	Activity	No. III-a-	Activity
112	D	114	F	117	D
120	E	121	A	122	C
123	A	124	C	125	A
131	A	132	F	133	F
134	D	135	C	139	D
140	D	141	D	142	D
144	E	145	D	147	D
148	D	149	D	150	D
151	D	152	D	153	D
154	D	155	D	157	D
158	D	159	D	160	E
161	E	162	D	163	D
166	E	168	F	169	E
170	F	171	F	172	F
173	E	174	D	175	D
176	D	177	D	178	D
179	D	180	F	184	E
188	E	189	D	190	E
191	D	192	E	193	D
194	D	195	D	196	D
197	F	198	D	199	D
200	D	201	D	202	D
203	D	204	D	205	D
206	D	207	D	208	D
209	D	210	D	211	D
212	D	213	D	214	D
215	D	216	D	217	D
218	E	219	D	220	D
221	D	222	D	223	D
224	D	225	D	226	D
227	D	229	E	230	D

No. III-a-	Activity	No. III-a-	Activity	No. III-a-	Activity
231	D	232	D	233	D
234	D	235	D	236	D
237	D	238	D	-	-

Example 31

ERK2 INHIBITION: Cell Proliferation Assay

Compounds may be assayed for the inhibition of ERK2 by a cell proliferation assay. In this assay, a complete media is prepared by adding 10% fetal bovine serum and penicillin/streptomycin solution to RPMI 1640 medium (JRH Biosciences). Colon cancer cells (HT-29 cell line) are added to each of 84 wells of a 96 well plate at a seeding density of 10,000 cells/well/150 µL. The cells are allowed to attach to the plate by incubating at 37°C for 2 hours. A solution of test compound is prepared in complete media by serial dilution to obtain the following concentrations: 20 µM, 6.7 µM, 2.2 µM, 0.74 µM, 0.25 µM, and 0.08 µM. The test compound solution (50 µL) is added to each of 72 cell-containing wells. To the 12 remaining cell-containing wells, only complete media (200 µL) is added to form a control group in order to measure maximal proliferation. To the remaining 12 empty wells, complete media is added to form a vehicle control group in order to measure background. The plates are incubated at 37°C for 3 days. A stock solution of ³H-thymidine (1 mCi/mL, New England Nuclear, Boston, MA) is diluted to 20 µCi/mL in RPMI medium then 20 µL of this solution is added to each well. The plates are further incubated at 37°C for 8

hours then harvested and analyzed for ^3H -thymidine uptake using a liquid scintillation counter.

Compounds III-a-116, III-a-139, and III-a-136 were each shown to have an IC_{50} of less than 0.1 μM .

5

Example 32

ERK1 INHIBITION ASSAY

Compounds were assayed for the inhibition of ERK1 by a spectrophotometric coupled-enzyme assay (Fox et al (1998) *Protein Sci* 7, 2249). In this assay, a fixed concentration of activated ERK1 (20 nM) was incubated with various concentrations of the compound in DMSO (2.0 %) for 10 min. at 30°C in 0.1 M HEPES buffer, pH 7.6, containing 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200 μM NADH, 30 $\mu\text{g/mL}$ pyruvate kinase, 10 $\mu\text{g/mL}$ lactate dehydrogenase, and 150 μM erktide peptide. The reaction was initiated by the addition of 140 μM ATP (20 μL). The rate of decrease of absorbance at 340 nM was monitored. The K_i was evaluated from the rate data as a function of inhibitor concentration.

Examples of compounds that were found to inhibit ERK1 with an activity of less than 0.1 μM include III-a-202, III-a-204, and III-a-205.

25

Example 33

GSK-3 INHIBITION ASSAY

Compounds were screened for their ability to inhibit GSK-3 β (AA 1-420) activity using a standard coupled enzyme system (Fox et al. (1998) *Protein Sci.* 7, 2249). Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate

2000/7/15 9:02:08 AM

concentrations in the assay were 20 μ M ATP (Sigma Chemicals, St Louis, MO) and 300 μ M peptide (HSSPHQS(PO₃H₂)EDEEE, American Peptide, Sunnyvale, CA).

Reactions were carried out at 30 °C and 20 nM GSK-3 β .

5 Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μ M NADH, 30 μ g/ml pyruvate kinase and 10 μ g/ml lactate dehydrogenase.

An assay stock buffer solution was prepared

10 containing all of the reagents listed above with the exception of ATP and the test compound of interest. The assay stock buffer solution (175 μ l) was incubated in a 96 well plate with 5 μ l of the test compound of interest at final concentrations spanning 0.002 μ M to 30 μ M at 30
15 °C for 10 min. Typically, a 12 point titration was conducted by preparing serial dilutions (from 10 mM compound stocks) with DMSO of the test compounds in daughter plates. The reaction was initiated by the addition of 20 μ l of ATP (final concentration 20 μ M).
20 Rates of reaction were obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, CA) over 10 min at 30°C. The K_i values were determined from the rate data as a function of inhibitor concentration.

Table 5 shows the results of the activity of
25 selected compounds of this invention in the GSK3 inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having an activity designated as "A" provided a K_i of less than 0.1 micromolar; compounds having an activity designated as
30 "B" provided a K_i of between 0.1 and 1.0 micromolar; and compounds having an activity designated as "C" provided a K_i of greater than 1.0 micromolar.

100-4759-1020802

Table 5. GSK3 Inhibitory Activity of Selected Compounds

No. IIIa-	Activity	No. IIIa-	Activity	No. IIIa-	Activity
116	A	117	A	134	C
136	A	137	A	138	A
139	A	140	A	141	A
142	A	144	C	145	A
146	B	147	A	148	A
149	A	150	B	151	A
152	A	153	A	154	A
155	B	156	B	157	A
158	A	159	A	162	A
166	C	172	C	173	C
174	A	175	B	176	A
177	B	178	B	179	A
181	C	184	C	187	C
188	C	189	C	190	B
191	B	193	B	194	A
196	C	198	C	199	A
200	C	201	B	202	C
203	B	205	B	206	A
207	B	208	A	209	A
210	C	211	B	212	A
213	B	214	B	215	A
216	A	217	A	222	B
223	A	224	A	225	A
227	C	228	A	230	B
231	A	232	B	233	C

400071699 - 020080E

Example 34

AURORA-2 INHIBITION ASSAY

Compounds were screened in the following manner for their ability to inhibit Aurora-2 using a standard
5 coupled enzyme assay (Fox et al (1998) *Protein Sci* 7, 2249).

To an assay stock buffer solution containing 0.1M HEPES 7.5, 10 mM MgCl₂, 1 mM DTT, 25 mM NaCl, 2.5 mM phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate
10 kinase, 10 mg/ml lactate dehydrogenase, 40 mM ATP, and 800 μ M peptide (LRRASLG, American Peptide, Sunnyvale, CA) was added a DMSO solution of a compound of the present invention to a final concentration of 30 μ M. The resulting mixture was incubated at 30 °C for 10 min. The reaction was initiated by the addition of 10 μ L of Aurora-2 stock solution to give a final concentration of 70 nM in the assay. The rates of reaction were obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30 °C using a BioRad Ultramark plate reader
15 (Hercules, CA). The K_i values were determined from the rate data as a function of inhibitor concentration.
Examples of compounds that were found to inhibit Aurora-2 include III-a-116, III-a-117, III-a-136, III-a-138, III-a-139, III-a-140, and III-a-141.

25

Example 35

CDK-2 INHIBITION ASSAY

Compounds were screened in the following manner for their ability to inhibit CDK-2 using a standard
30 coupled enzyme assay (Fox et al (1998) *Protein Sci* 7, 2249).

To an assay stock buffer solution containing 0.1M HEPES 7.5, 10 mM MgCl₂, 1 mM DTT, 25 mM NaCl, 2.5 mM

200071599-0000002

phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate kinase, 10 mg/ml lactate dehydrogenase, 100 mM ATP, and 100 μ M peptide (MAHHHRSPRKRAKKK, American Peptide,

Sunnyvale, CA) was added a DMSO solution of a compound of 5 the present invention to a final concentration of 30 μ M. The resulting mixture was incubated at 30 °C for 10 min.

The reaction was initiated by the addition of 10 μ L of CDK-2/Cyclin A stock solution to give a final concentration of 25 nM in the assay. The rates of

10 reaction were obtained by monitoring absorbance at 340 nm over a 5-minute read time at 30 °C using a BioRad Ultramark plate reader (Hercules, CA). The K_i values were determined from the rate data as a function of inhibitor concentration.

15 The following compounds were shown to have K_i values than 0.1 μ M for CDK-2: III-a-116, III-a-142, III-a-149, and III-a-152.

20 The following compounds were shown to have K_i values between 0.1 μ M and 1 μ M for CDK-2: III-a-146, III-a-148, III-a-150, III-a-155, III-a-162, and III-a-174.

The following compounds were shown to have K_i values between 1.0 and 20.0 μ M for CDK-2: III-a-117, III-a-156, and III-a-159.

25 Example 36

LCK INHIBITION ASSAY

The compounds were evaluated as inhibitors of human Lck kinase using either a radioactivity-based assay or spectrophotometric assay.

30 Lck Inhibition Assay A: Radioactivity-based Assay

The compounds were assayed as inhibitors of full length bovine thymus Lck kinase (from Upstate

Biotechnology, cat. no. 14-106) expressed and purified from baculo viral cells. Lck kinase activity was monitored by following the incorporation of ^{33}P from ATP into the tyrosine of a random poly Glu-Tyr polymer

5 substrate of composition, Glu:Tyr = 4:1 (Sigma, cat. no. P-0275). The following were the final concentrations of the assay components: 0.025 M HEPES, pH 7.6, 10 mM MgCl₂, 2 mM DTT, 0.25 mg/ml BSA, 10 μM ATP (1-2 μCi ^{33}P -ATP per reaction), 5 mg/ml poly Glu-Tyr, and 1-2 units of
10 recombinant human Src kinase. In a typical assay, all the reaction components with the exception of ATP were pre-mixed and aliquoted into assay plate wells. Inhibitors dissolved in DMSO were added to the wells to give a final DMSO concentration of 2.5%. The assay plate
15 was incubated at 30 C for 10 min before initiating the reaction with ^{33}P -ATP. After 20 min of reaction, the reactions were quenched with 150 μl of 10% trichloroacetic acid (TCA) containing 20 mM Na₃PO₄. The quenched samples were then transferred to a 96-well
20 filter plate (Whatman, UNI-Filter GF/F Glass Fiber Filter, cat no. 7700-3310) installed on a filter plate vacuum manifold. Filter plates were washed four times with 10% TCA containing 20 mM Na₃PO₄ and then 4 times with methanol. 200 μl of scintillation fluid was then added to
25 each well. The plates were sealed and the amount of radioactivity associated with the filters was quantified on a TopCount scintillation counter. The radioactivity incorporated was plotted as a function of the inhibitor concentration. The data was fitted to a competitive
30 inhibition kinetics model to get the Ki for the compound.

Lck Inhibition Assay B: Spectrophotometric Assay

The ADP produced from ATP by the human recombinant Lck kinase-catalyzed phosphorylation of poly Glu-Tyr substrate was quantified using a coupled enzyme

5 assay (Fox et al (1998) *Protein Sci* 7, 2249). In this assay one molecule of NADH is oxidised to NAD for every molecule of ADP produced in the kinase reaction. The disappearance of NADH can be conveniently followed at 340 nm.

10 The following were the final concentrations of the assay components: 0.025 M HEPES, pH 7.6, 10 mM MgCl₂, 2 mM DTT, 5 mg/ml poly Glu-Tyr, and 50 nM of recombinant human Lck kinase. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 200 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.

15 In a typical assay, all the reaction components with the exception of ATP were pre-mixed and aliquoted into assay plate wells. Inhibitors dissolved in DMSO 20 were added to the wells to give a final DMSO concentration of 2.5%. The assay plate was incubated at 30 °C for 10 min before initiating the reaction with 150 μM ATP. The absorbance change at 340 nm with time, the rate of the reaction, was monitored on a molecular 25 devices plate reader. The data of rate as a function of the inhibitor concentration was fitted to competitive inhibition kinetics model to get the K_i for the compound.

30 The following compounds were shown to have K_i values than 1 μM for Lck: III-a-170, III-a-171, III-a-172, III-a-173, III-a-181, and III-a-203.

20071699-020302

The following compounds were shown to have K_i values between 1.0 and 20.0 μM for Lck: III-a-204, III-a-205, III-a-206, and III-a-207.

5

Example 37

AKT3 INHIBITION ASSAY

Compounds were screened for their ability to inhibit AKT3 using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249). Assays were carried out in a mixture of 100 mM HEPES 7.5, 10 mM MgCl₂, 25 mM NaCl, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 170 μM ATP (Sigma Chemicals) and 200 μM peptide (RPRAATF, American Peptide, Sunnyvale, CA). Assays were carried out at 30 °C and 45 nM AKT3. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 $\mu\text{g}/\text{ML}$ pyruvate kinase and 10 $\mu\text{g}/\text{ml}$ lactate dehydrogenase.

An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of AKT3, DTT, and the test compound of interest. 56 μl of the stock solution was placed in a 384 well plate followed by addition of 1 μl of 2 mM DMSO stock containing the test compound (final compound concentration 30 μM). The plate was preincubated for about 10 minutes at 30 °C and the reaction initiated by addition of 10 μl of enzyme (final concentration 45 nM) and 1 mM DTT. Rates of reaction were obtained using a BioRad Ultramark plate reader (Hercules, CA) over a 5 minute read time at 30 °C. Compounds showing greater than 50% inhibition versus standard wells containing the assay mixture and DMSO without test compound were titrated to determine IC₅₀ values.

100071694 - 02030224

Selected compounds of this invention that inhibit AKT3 include: **III-a-238**.

While we have presented a number of embodiments of this invention, it is apparent that our basic

5 construction can be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments which have
10 been represented by way of example.

10071695.0208012

Appendix A: Names of Table 1 Compound Numbers III-a-

1: 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide;
5 2: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-pyrrolidin-1-yl-methanone;
3: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-pyrrolidin-1-yl-methanone;
10 4: 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
5: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
15 6: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[1,4']bipiperidinyl-1'-yl-methanone;
7: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3-hydroxy-piperidin-1-yl)-methanone;
20 8: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[1,4']bipiperidinyl-1'-yl-methanone;
9: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[1,4']bipiperidinyl-1'-yl-methanone;
10: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[1,4']bipiperidinyl-1'-yl-methanone;
25 11: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-4-hydroxy-piperidin-1-yl)-methanone;
12: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;
30 13: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-phenyl-piperazin-1-yl]-methanone;
14: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;
35 15: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-pyridin-2-yl-piperazin-1-yl]-methanone;
16: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-morpholin-4-yl-methanone;
40 17: 4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;
18: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-morpholin-4-yl-methanone;
45 19: 4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

20: 4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

5 21: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;

22: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-phenyl-piperazin-1-yl)-methanone;

10 23: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;

15 24: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;

25 25: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-pyridin-2-yl-piperazin-1-yl)-methanone;

26: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-morpholin-4-yl-methanone;

20 27: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-hydroxy-piperidin-1-yl)-methanone;

28: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[1,4']bipiperidinyl-1'-yl-methanone;

25 29: 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

30 30: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;

31: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(2-hydroxymethyl-piperidin-1-yl)-methanone;

30 32: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;

33: 4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

35 34: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;

35: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;

40 36: 4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

37: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-phenyl-piperazin-1-yl)-methanone;

45 38: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-methyl-[1,4]diazepan-1-yl)-methanone;

39: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone;

40: 4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

41: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;

5 42: 4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

43: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;

10 44: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-phenyl-piperazin-1-yl)-methanone;

45: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;

15 46: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[3-hydroxy-piperidin-1-yl]-methanone;

47: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;

20 48: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-methanone;

49: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(2-fluoro-phenyl)-piperazin-1-yl]-methanone;

25 50: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methanone;

51: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;

30 52: 1-(4-{4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carbonyl}-piperazin-1-yl)-ethanone;

53: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[3,4-dihydro-1H-isoquinolin-2-yl]-methanone;

35 54: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(3-hydroxy-piperidin-1-yl)-methanone;

55: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-
40 (4-methyl-[1,4]diazepan-1-yl)-methanone;

56: 1-(4-{4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carbonyl}-piperazin-1-yl)-ethanone;

57: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-methyl-[1,4]diazepan-1-yl)-methanone;

45 58: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-
 (3-hydroxy-piperidin-1-yl)-methanone;

5 59: 4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide;

60: [4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;

61: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-[2-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone;

62: 4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

63: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-pyridin-2-yl-piperazin-1-yl)-methanone;

64: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-(4-hydroxy-piperidin-1-yl)-methanone;

65: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-hydroxy-piperidin-1-yl)-methanone;

66: {4-[2-Amino-5-(3-chloro-2-fluoro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-hydroxy-piperidin-1-yl)-methanone;

67: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-pyridin-2-yl-piperazin-1-yl)-methanone;

68: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-(2-hydroxy-ethyl)-piperazin-1-yl)-methanone;

69: {4-[4-(2-Amino-5-m-tolyl-pyrimidin-4-yl)-1H-pyrrole-2-carbonyl]-piperazin-1-yl}-ethanone;

70: {4-[2-Amino-5-(3,4-dimethoxy-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-(4-(2-fluoro-phenyl)-piperazin-1-yl)-methanone;

71: [4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrol-2-yl]-pyrrolidin-1-yl-methanone;

72: {4-[2-Amino-5-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-pyrrol-2-yl}-morpholin-4-yl-methanone;

73: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzylamide;

74: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;

75: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

76: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 4-fluoro-benzylamide;

77: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-benzylamide;

78: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 4-methoxy-benzylamide;

79: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

80: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;

81: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;

82: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

83: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

84: 4-(2,5-Diamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

85: 4-(2-Amino-5-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

86: 4-(5-Acetyl-amino-2-amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

87: 4-[2-Amino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

88: 4-(2-Amino-5-hydroxy-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

89: 4-(2-Amino-5-methylaminomethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

90: 4-(2-Amino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

91: 4-[2-Cyclohexylamino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

92: 4-[2-Acetyl-amino-5-(3-methyl-ureido)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

93: 4-(5-Hydroxy-2-methanesulfonylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

94: 4-(2-Amino-5-methanesulfonyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3-chloro-4-fluoro-benzylamide;

95: 4-(2-Amino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;

96: 4-(2-Cyclohexylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 3,4-difluoro-benzylamide;

97: 4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (pyridin-4-ylmethyl)-amide;

98: 4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3-trifluoromethyl-benzylamide;

JM0071659 - 02/08/2022

99: 4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

100: 4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;

101: 4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-dimethylamino-2-pyridin-3-yl-ethyl)-amide;

102: 4-[2-Amino-5-(3,5-dichloro-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 4-methanesulfonyl-benzylamide;

103: 4-[5-(3-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;

104: 4-[5-(3,5-Dichloro-phenyl)-2-phenylamino-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-2-pyridin-3-yl-ethyl)-amide;

105: 4-[2-Amino-5-(3-fluoro-5-trifluoromethyl-phenyl)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

106: 4-(2-Amino-5-propyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

107: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

108: 4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

109: 4-(2-Methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide;

110: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-dimethylamino-ethyl)-amide;

111: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid propylamide;

112: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-phenyl-propyl)-amide;

113: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (naphthalen-1-ylmethyl)-amide;

114: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid cyclopropylamide;

115: 4-(2-Ethylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid 2-trifluoromethyl-benzylamide;

116: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

117: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

118: 4-(2-Ethylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (4-methyl-cyclohexyl)-amide;

119: 4-(5-Ethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid isopropylamide;

120: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-amino-ethyl)-amide;

5 121: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid benzyl-methyl-amide;

122: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

10 123: 1-{4-[4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carbonyl]-piperazin-1-yl}-ethanone;

124: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (3-phenyl-propyl)-amide;

15 125: 4-(2-Amino-5-ethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-(6-methoxy-1H-indol-3-yl)-ethyl]-amide;

126: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-phenoxy-ethyl)-amide;

127: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1-methyl-3-phenyl-propyl)-amide;

20 128: 4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1H-benzimidazol-2-ylmethyl)-amide;

129: 4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (1-hydroxymethyl-3-methyl-butyl)-amide;

25 130: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-hydroxymethyl-2-(1H-imidazol-4-yl)-ethyl]-amide;

131: 4-(2-Amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide;

30 132: 4-[2-(2-Diethylamino-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid 3,4-difluorobenzylamide;

133: 4-[5-Methyl-2-(2-piperidin-1-yl-quinazolin-4-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid benzylamide;

134: 4-(5-Methyl-2-methylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluorophenyl)-2-hydroxy-ethyl]-amide;

40 135: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-4-fluorophenyl)-2-hydroxy-ethyl]-amide;

45 136: 4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

137: 4-[2-(3-Methoxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

138: 4-[2-(3-Hydroxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

139: 4-[2-(Benzo[1,3]dioxol-5-ylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

140: 4-[5-Methyl-2-(4-sulfamoyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

141: 4-[2-(3-Benzylxyloxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

142: 4-[2-(4-Hydroxy-cyclohexylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

143: 4-(5-Cyclohexyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

144: 4-(5-Cyclopropyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

145: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-amide;

146: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

147: 4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-amide;

148: 4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

149: 4-[5-Methyl-2-(3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

150: 4-(2-Benzylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

151: 4-[2-(3,4-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

152: 4-[2-(4-Benzylxyloxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

153: 4-(2-Isopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

154: 4-[5-Methyl-2-(2,2,2-trifluoro-ethylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

155: 4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

156: 4-[2-(2-Methoxy-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

157: 4-[5-Methyl-2-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

158: 4-(2-Isobutylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

159: 4-[2-(Cyclopropylmethyl-amino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

160: 4-(5-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

161: 4-(2-Amino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

162: 4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

163: 4-(5-Methyl-2-propylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

164: 4-(5-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

165: 4-(5-Hydroxymethyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

166: 4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

167: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

168: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-amide;

169: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carboxylic acid (2-hydroxy-2-phenyl-ethyl)-amide;

170: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carboxylic acid (2-hydroxy-1-hydroxymethyl-2-
phenyl-ethyl)-amide;

171: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carboxylic acid (2-hydroxy-1-hydroxymethyl-2-
phenyl-ethyl)-amide;

172: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

173: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-
2-carboxylic acid (3-hydroxy-1-phenyl-propyl)-amide;

174: 4-[2-(1-Hydroxymethyl-cyclopropylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-
hydroxy-1-phenyl-ethyl)-amide;

175: 4-[2-(2-Hydroxy-ethylamino)-5-methyl-pyrimidin-4-
yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-
phenyl-ethyl)-amide;

176: 4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-
hydroxy-1-phenyl-ethyl)-amide;

177: 4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-
yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-
phenyl-ethyl)-amide;

178: 4-[2-(2-Hydroxy-propylamino)-5-methyl-pyrimidin-4-
yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-
phenyl-ethyl)-amide;

179: 4-[2-(2-Hydroxy-cyclohexylamino)-5-methyl-pyrimidin-
4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-
phenyl-ethyl)-amide;

121: 4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-
hydroxy-1-phenyl-ethyl)-amide;

121: 4-[2-(3-Dimethylamino-phenylamino)-5-methyl-
pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-
hydroxy-1-phenyl-ethyl)-amide;

180: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic
acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-
amide;

181: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic
acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-
amide;

183: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic
acid (2-hydroxy-2-phenyl-ethyl)-methyl-amide;

184: {[4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-
pyrrole-2-carbonyl]-amino}-phenyl-acetic acid methyl
ester;

186: 4-(2-Amino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide;

187: 4-(2-Ethylamino-5-methoxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

188: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-pyridin-3-yl-ethyl)-amide;

189: 4-(2-Ethylamino-5-hydroxymethyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

190: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-ethyl]-amide;

191: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

192: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(2-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

193: 4-[2-(2-Cyclopropyl-1-hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

194: 4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

195: 4-(2-Ethoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

196: 4-[2-(1-Hydroxymethyl-2-methyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

197: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-oxo-1-phenyl-propyl)-amide;

198: 4-(2-Ethylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

199: 4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

200: 4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

201: 4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

200: 4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

202: 4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(3-trifluoromethyl-phenyl)-ethyl]-amide;

203: 4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [2-hydroxy-1-(2-methoxy-phenyl)-ethyl]-amide;

204: 4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

205: 4-(2-Cyclopropylamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

206: 4-(2-Methoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

207: 4-(2-Isopropoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

208: 4-[2-(3-Dimethylamino-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

209: 4-[2-(2-Chloro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

210: 4-[2-(2-Hydroxy-1-phenyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

211: 4-[2-(2,3-Dimethyl-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

212: 4-[2-(3-Fluoro-phenylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

213: 4-(2-Acetyl-amino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

214: 4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

215: 4-[5-Methyl-2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

216: 4-[5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

100071899 - 0200802

217: 4-{5-Methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

218: N'-{4-[5-(2-Hydroxy-1-phenyl-ethylcarbamoyl)-1H-pyrrol-3-yl]-5-methyl-pyrimidin-2-yl}-hydrazinecarboxylic acid ethyl ester;

219: 4-{5-Methyl-2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

220: 4-(2-Cyclopropylmethoxyamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

221: 4-[2-(Isoxazol-3-ylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

222: 4-[2-(2-Hydroxy-1-methyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

223: 4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

224: 4-(5-Methyl-2-o-tolylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

225: 4-[2-(2-Hydroxy-ethoxyamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

226: 4-[2-(N',N'-Dimethyl-hydrazino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

227: 4-[5-Methyl-2-(2-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

228: 4-[5-Methyl-2-(morpholin-4-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

229: 4-[5-Methyl-2-(5-methyl-isoxazol-3-ylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

230: 4-{2-[1-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-5-methyl-pyrimidin-4-yl}-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

231: 4-(5-Methyl-2-phenylamino-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-fluoro-phenyl)-2-hydroxy-ethyl]-amide;

232: 4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

233: 4-[2-(2-Hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid [1-(3-chloro-phenyl)-2-hydroxy-ethyl]-amide;

234: 4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-m-tolyl-ethyl)-amide;

235: 4-[2-(2-Hydroxymethyl-ethylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

236: 4-[2-(1-Hydroxymethyl-propylamino)-5-methyl-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide;

237: 4-[5-Methyl-2-(2-methyl-cyclopropylamino)-pyrimidin-4-yl]-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide; and

238: 4-(2-Cyanoamino-5-methyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid (2-hydroxy-1-phenyl-ethyl)-amide.